{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:01:49Z","timestamp":1789804909184,"version":"4.0.1"},"reference-count":453,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10381-8","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:47:02Z","timestamp":1789796822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision therapeutic strategies for advanced gastrointestinal stromal tumors"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-5775","authenticated-orcid":false,"given":"Akira","family":"Ooki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Shimozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"10381_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/PAS.0000000000001552","volume":"45","author":"ME Kallen","year":"2021","unstructured":"Kallen, M. E., & Hornick, J. L. (2021). The 2020 WHO classification: What\u2019s new in soft tissue tumor pathology? American Journal of Surgical Pathology, 45, e1\u2013e23.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246958","volume":"16","author":"G de Pinieux","year":"2021","unstructured":"de Pinieux, G., Karanian, M., Le Loarer, F., et al. (2021). Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE, 16, Article e0246958.","journal-title":"PLoS ONE"},{"key":"10381_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/cncr.20862","volume":"103","author":"B Nilsson","year":"2005","unstructured":"Nilsson, B., B\u00fcmming, P., Meis-Kindblom, J. M., et al. (2005). Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era\u2013A population-based study in western Sweden. Cancer, 103, 821\u2013829.","journal-title":"Cancer"},{"key":"10381_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide, K., Sandvik, O. M., S\u00f8reide, J. A., Giljaca, V., Jureckova, A., & Bulusu, V. R. (2016). Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiology, 40, 39\u201346.","journal-title":"Cancer Epidemiology"},{"key":"10381_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","volume":"7","author":"JY Blay","year":"2021","unstructured":"Blay, J. Y., Kang, Y. K., Nishida, T., & von Mehren, M. (2021). Gastrointestinal stromal tumours. Nature Reviews. Disease Primers, 7, 22.","journal-title":"Nature Reviews. Disease Primers"},{"key":"10381_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112994","author":"RJ Vaamonde-Mart\u00edn","year":"2023","unstructured":"Vaamonde-Mart\u00edn, R. J., Ballesta-Ruiz, M., S\u00e1nchez-Gil, A., et al. (2023). Incidence trends and main features of gastro-intestinal stromal tumours in a Mediterranean region: A population-based study. Cancers. https:\/\/doi.org\/10.3390\/cancers15112994","journal-title":"Cancers"},{"key":"10381_CR7","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1016\/j.ejca.2005.09.009","volume":"41","author":"WG Goettsch","year":"2005","unstructured":"Goettsch, W. G., Bos, S. D., Breekveldt-Postma, N., Casparie, M., Herings, R. M., & Hogendoorn, P. C. (2005). Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. European Journal of Cancer, 41, 2868\u20132872.","journal-title":"European Journal of Cancer"},{"key":"10381_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1055-9965.EPI-14-1002","volume":"24","author":"GL Ma","year":"2015","unstructured":"Ma, G. L., Murphy, J. D., Martinez, M. E., & Sicklick, J. K. (2015). Epidemiology of gastrointestinal stromal tumors in the era of histology codes: Results of a population-based study. Cancer Epidemiology, Biomarkers & Prevention, 24, 298\u2013302.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"10381_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali, P. G., Blay, J. Y., Abecassis, N., et al. (2022). Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 33, 20\u201333.","journal-title":"Annals of Oncology"},{"key":"10381_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00000478-199904000-00002","volume":"23","author":"K Sircar","year":"1999","unstructured":"Sircar, K., Hewlett, B. R., Huizinga, J. D., Chorneyko, K., Berezin, I., & Riddell, R. H. (1999). Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. American Journal of Surgical Pathology, 23, 377\u2013389.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota, S., Isozaki, K., Moriyama, Y., et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577\u2013580.","journal-title":"Science"},{"key":"10381_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich, M. C., Corless, C. L., Duensing, A., et al. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299, 708\u2013710.","journal-title":"Science"},{"key":"10381_CR13","first-page":"1259","volume":"152","author":"LG Kindblom","year":"1998","unstructured":"Kindblom, L. G., Remotti, H. E., Aldenborg, F., & Meis-Kindblom, J. M. (1998). Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology, 152, 1259\u20131269.","journal-title":"American Journal of Pathology"},{"key":"10381_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nature09409","volume":"467","author":"P Chi","year":"2010","unstructured":"Chi, P., Chen, Y., Zhang, L., et al. (2010). ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 467, 849\u2013853.","journal-title":"Nature"},{"key":"10381_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0016-5085(03)01046-1","volume":"125","author":"S Hirota","year":"2003","unstructured":"Hirota, S., Ohashi, A., Nishida, T., et al. (2003). Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology, 125, 660\u2013667.","journal-title":"Gastroenterology"},{"key":"10381_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri, G. D., von Mehren, M., Blanke, C. D., et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine, 347, 472\u2013480.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13569-019-0114-5","volume":"9","author":"JW Call","year":"2019","unstructured":"Call, J. W., Wang, Y., Montoya, D., Scherzer, N. J., & Heinrich, M. C. (2019). Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: Results from Life Raft Group Registry. Clin Sarcoma Res., 9, 4.","journal-title":"Clin Sarcoma Res."},{"key":"10381_CR18","unstructured":"The National Comprehensive Cancer Network. (2026). NCCN clinical practice guidelines in oncology, Gastrointestinal stromal tumors. version 1. \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gist.pdf\u00a0"},{"key":"10381_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10147-024-02488-1","volume":"29","author":"S Hirota","year":"2024","unstructured":"Hirota, S., Tateishi, U., Nakamoto, Y., et al. (2024). English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. International Journal of Clinical Oncology, 29, 647\u2013680.","journal-title":"International Journal of Clinical Oncology"},{"key":"10381_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101928","author":"A Kalfusova","year":"2023","unstructured":"Kalfusova, A., Krskov\u00e1, L., Copikova, J., et al. (2023). 118P Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101928","journal-title":"ESMO Open"},{"key":"10381_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf110","author":"J Li","year":"2025","unstructured":"Li, J., Sun, L., Liu, S., et al. (2025). Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations. The Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf110","journal-title":"The Oncologist"},{"key":"10381_CR22","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich, M. C., Corless, C. L., Blanke, C. D., et al. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Journal of Clinical Oncology, 24, 4764\u20134774.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/path.2382","volume":"216","author":"B Liegl","year":"2008","unstructured":"Liegl, B., Kepten, I., Le, C., et al. (2008). Heterogeneity of kinase inhibitor resistance mechanisms in GIST. The Journal of Pathology, 216, 64\u201374.","journal-title":"The Journal of Pathology"},{"key":"10381_CR24","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann, E., Merkelbach-Bruse, S., Pauls, K., et al. (2006). Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clinical Cancer Research, 12, 1743\u20131749.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR25","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu, C. R., Besmer, P., Guo, T., et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical Cancer Research, 11, 4182\u20134190.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2214\/ajr.183.6.01831619","volume":"183","author":"H Choi","year":"2004","unstructured":"Choi, H., Charnsangavej, C., de Castro, F. S., et al. (2004). CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR. American Journal of Roentgenology, 183, 1619\u20131628.","journal-title":"AJR. American Journal of Roentgenology"},{"issue":"Suppl 2","key":"10381_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","volume":"13","author":"H Choi","year":"2008","unstructured":"Choi, H. (2008). Response evaluation of gastrointestinal stromal tumors. The Oncologist, 13(Suppl 2), 4\u20137.","journal-title":"The Oncologist"},{"key":"10381_CR28","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi, H., Charnsangavej, C., Faria, S. C., et al. (2007). Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. Journal of Clinical Oncology, 25, 1753\u20131759.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/tgh.2018.04.01","volume":"3","author":"S Hirota","year":"2018","unstructured":"Hirota, S. (2018). Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry. Transl Gastroenterol Hepatol., 3, 27.","journal-title":"Transl Gastroenterol Hepatol."},{"key":"10381_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/106689690201000201","volume":"10","author":"CD Fletcher","year":"2002","unstructured":"Fletcher, C. D., Berman, J. J., Corless, C., et al. (2002). Diagnosis of gastrointestinal stromal tumors: A consensus approach. International Journal of Surgical Pathology, 10, 81\u201389.","journal-title":"International Journal of Surgical Pathology"},{"key":"10381_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","volume":"23","author":"M Miettinen","year":"2006","unstructured":"Miettinen, M., & Lasota, J. (2006). Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology, 23, 70\u201383.","journal-title":"Seminars in Diagnostic Pathology"},{"key":"10381_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/SLA.0000000000003277","volume":"273","author":"MJ Cavnar","year":"2021","unstructured":"Cavnar, M. J., Seier, K., Curtin, C., et al. (2021). Outcome of 1000 patients with gastrointestinal stromal tumor (GIST) treated by surgery in the pre- and post-imatinib eras. Annals of Surgery, 273, 128\u2013138.","journal-title":"Annals of Surgery"},{"key":"10381_CR33","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri, G. D., van Oosterom, A. T., Garrett, C. R., et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet, 368, 1329\u20131338.","journal-title":"Lancet"},{"key":"10381_CR34","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004). Biology of gastrointestinal stromal tumors. Journal of Clinical Oncology, 22, 3813\u20133825.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2559.2005.02291.x","volume":"48","author":"BP Rubin","year":"2006","unstructured":"Rubin, B. P. (2006). Gastrointestinal stromal tumours: An update. Histopathology, 48, 83\u201396.","journal-title":"Histopathology"},{"key":"10381_CR36","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/PAS.0b013e3181a90e1a","volume":"33","author":"M Miettinen","year":"2009","unstructured":"Miettinen, M., Wang, Z. F., & Lasota, J. (2009). DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases. American Journal of Surgical Pathology, 33, 1401\u20131408.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/modpathol.3880210","volume":"13","author":"M Miettinen","year":"2000","unstructured":"Miettinen, M., Sobin, L. H., & Sarlomo-Rikala, M. (2000). Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Modern Pathology, 13, 1134\u20131142.","journal-title":"Modern Pathology"},{"key":"10381_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0002-9440(10)63279-8","volume":"165","author":"RB West","year":"2004","unstructured":"West, R. B., Corless, C. L., Chen, X., et al. (2004). The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. American Journal of Pathology, 165, 107\u2013113.","journal-title":"American Journal of Pathology"},{"key":"10381_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/00000478-200407000-00007","volume":"28","author":"F Medeiros","year":"2004","unstructured":"Medeiros, F., Corless, C. L., Duensing, A., et al. (2004). KIT-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications. American Journal of Surgical Pathology, 28, 889\u2013894.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5858\/134.2.165","volume":"134","author":"BP Rubin","year":"2010","unstructured":"Rubin, B. P., Blanke, C. D., Demetri, G. D., et al. (2010). Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Archives of Pathology and Laboratory Medicine, 134, 165\u2013170.","journal-title":"Archives of Pathology and Laboratory Medicine"},{"key":"10381_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","volume":"231","author":"RP DeMatteo","year":"2000","unstructured":"DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000). Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Annals of Surgery, 231, 51\u201358.","journal-title":"Annals of Surgery"},{"key":"10381_CR42","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s10120-014-0386-7","volume":"18","author":"Y Yanagimoto","year":"2015","unstructured":"Yanagimoto, Y., Takahashi, T., Muguruma, K., et al. (2015). Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: Indications for adjuvant therapy. Gastric Cancer, 18, 426\u2013433.","journal-title":"Gastric Cancer"},{"key":"10381_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","volume":"13","author":"H Joensuu","year":"2012","unstructured":"Joensuu, H., Vehtari, A., Riihim\u00e4ki, J., et al. (2012). Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. The lancet Oncology, 13, 265\u2013274.","journal-title":"The lancet Oncology"},{"key":"10381_CR44","doi-asserted-by":"crossref","unstructured":"Demetri, G.D, Benjamin, R.S, Blanke, C.D, et al.\u00a0(2007). NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST)--Update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2), S1\u201329 quiz S30.","DOI":"10.6004\/jnccn.2007.2002"},{"key":"10381_CR45","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","volume":"39","author":"H Joensuu","year":"2008","unstructured":"Joensuu, H. (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology, 39, 1411\u20131419.","journal-title":"Human Pathology"},{"key":"10381_CR46","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(09)70242-6","volume":"10","author":"JS Gold","year":"2009","unstructured":"Gold, J. S., G\u00f6nen, M., Guti\u00e9rrez, A., et al. (2009). Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. The lancet Oncology, 10, 1045\u20131052.","journal-title":"The lancet Oncology"},{"key":"10381_CR47","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1002\/cncr.29434","volume":"121","author":"JD Murphy","year":"2015","unstructured":"Murphy, J. D., Ma, G. L., Baumgartner, J. M., et al. (2015). Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. Cancer, 121, 2960\u20132967.","journal-title":"Cancer"},{"key":"10381_CR48","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1245\/s10434-014-4332-z","volume":"22","author":"JF Hechtman","year":"2015","unstructured":"Hechtman, J. F., DeMatteo, R., Nafa, K., et al. (2015). Additional primary malignancies in patients with gastrointestinal stromal tumor (GIST): A clinicopathologic study of 260 patients with molecular analysis and review of the literature. Annals of Surgical Oncology, 22, 2633\u20132639.","journal-title":"Annals of Surgical Oncology"},{"key":"10381_CR49","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/ijc.30231","volume":"139","author":"MJ Smith","year":"2016","unstructured":"Smith, M. J., Smith, H. G., Mahar, A. L., Law, C., & Ko, Y. J. (2016). The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors. International Journal of Cancer, 139, 1744\u20131751.","journal-title":"International Journal of Cancer"},{"key":"10381_CR50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.semdp.2006.09.004","volume":"23","author":"A Agaimy","year":"2006","unstructured":"Agaimy, A., W\u00fcnsch, P. H., Sobin, L. H., Lasota, J., & Miettinen, M. (2006). Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Seminars in Diagnostic Pathology, 23, 120\u2013129.","journal-title":"Seminars in Diagnostic Pathology"},{"key":"10381_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.suronc.2019.03.001","volume":"29","author":"F Petrelli","year":"2019","unstructured":"Petrelli, F., Tomasello, G., Barni, S., et al. (2019). Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. Surgical Oncology, 29, 64\u201370.","journal-title":"Surgical Oncology"},{"key":"10381_CR52","doi-asserted-by":"publisher","first-page":"83270","DOI":"10.18632\/oncotarget.12452","volume":"7","author":"BR Lai","year":"2016","unstructured":"Lai, B. R., Wu, Y. T., Kuo, Y. C., et al. (2016). Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: Random or nonrandom, that is the question. Oncotarget, 7, 83270\u201383277.","journal-title":"Oncotarget"},{"key":"10381_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104116","volume":"105","author":"H Mechahougui","year":"2025","unstructured":"Mechahougui, H., Hildebrand, L., Haberberger, J., et al. (2025). Clinical use of liquid-based comprehensive genomic profiling in gastrointestinal stromal tumors. Laboratory Investigation, 105, Article 104116.","journal-title":"Laboratory Investigation"},{"key":"10381_CR54","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich, M. C., Corless, C. L., Demetri, G. D., et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology, 21, 4342\u20134349.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR55","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S1470-2045(15)70105-1","volume":"16","author":"JY Blay","year":"2015","unstructured":"Blay, J. Y., Shen, L., Kang, Y. K., et al. (2015). Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): A randomised phase 3 trial. Lancet Oncology, 16, 550\u2013560.","journal-title":"Lancet Oncology"},{"key":"10381_CR56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41571-022-00606-4","volume":"19","author":"LR Klug","year":"2022","unstructured":"Klug, L. R., Khosroyani, H. M., Kent, J. D., & Heinrich, M. C. (2022). New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nature Reviews. Clinical Oncology, 19, 328\u2013341.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10381_CR57","first-page":"3329","volume":"9","author":"CR Antonescu","year":"2003","unstructured":"Antonescu, C. R., Sommer, G., Sarran, L., et al. (2003). Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research, 9, 3329\u20133337.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/gcc.22923","volume":"60","author":"I Vanden Bempt","year":"2021","unstructured":"Vanden Bempt, I., Vander Borght, S., Sciot, R., et al. (2021). Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor. Genes, Chromosomes & Cancer, 60, 239\u2013249.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12943-023-01770-6","volume":"22","author":"B Li","year":"2023","unstructured":"Li, B., Chen, H., Yang, S., et al. (2023). Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers. Molecular Cancer, 22, 71.","journal-title":"Molecular Cancer"},{"key":"10381_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000335","volume":"3","author":"L Mavroeidis","year":"2018","unstructured":"Mavroeidis, L., Metaxa-Mariatou, V., Papoudou-Bai, A., et al. (2018). Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT\/PDGFRA genes and novel genomic alterations: Results from a 20-year cohort of patients with GIST from north-western Greece. ESMO Open., 3, Article e000335.","journal-title":"ESMO Open."},{"key":"10381_CR61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/PAP.0000000000000158","volume":"24","author":"IM Schaefer","year":"2017","unstructured":"Schaefer, I. M., Mari\u00f1o-Enr\u00edquez, A., & Fletcher, J. A. (2017). What is new in gastrointestinal stromal tumor? Advances in Anatomic Pathology, 24, 259\u2013267.","journal-title":"Advances in Anatomic Pathology"},{"key":"10381_CR62","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-23-1184","volume":"29","author":"JK Dermawan","year":"2023","unstructured":"Dermawan, J. K., Kelly, C., Gao, Z., et al. (2023). Novel genomic risk stratification model for primary gastrointestinal stromal tumors (GIST) in the adjuvant therapy era. Clinical Cancer Research, 29, 3974\u20133985.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-022-00342-z","volume":"7","author":"D Mandelker","year":"2023","unstructured":"Mandelker, D., Marra, A., Mehta, N., et al. (2023). Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. NPJ Precis Oncol., 7, 1.","journal-title":"NPJ Precis Oncol."},{"key":"10381_CR64","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/ajcp\/aqw193","volume":"146","author":"L Merten","year":"2016","unstructured":"Merten, L., Agaimy, A., Moskalev, E. A., et al. (2016). Inactivating mutations of RB1 and TP53 correlate with sarcomatous histomorphology and metastasis\/recurrence in gastrointestinal stromal tumors. American Journal of Clinical Pathology, 146, 718\u2013726.","journal-title":"American Journal of Clinical Pathology"},{"key":"10381_CR65","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s12032-011-0074-y","volume":"29","author":"JF Emile","year":"2012","unstructured":"Emile, J. F., Brahimi, S., Coindre, J. M., et al. (2012). Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Medical Oncology, 29, 1765\u20131772.","journal-title":"Medical Oncology"},{"key":"10381_CR66","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00284","volume":"8","author":"H Fujii","year":"2024","unstructured":"Fujii, H., Hirano, H., Shiraishi, K., et al. (2024). Comprehensive genomic assessment of advanced-stage GI stromal tumors using the Japanese National Center for Cancer Genomics and Advanced Therapeutics database. JCO Precision Oncology, 8, Article e2400284.","journal-title":"JCO Precision Oncology"},{"key":"10381_CR67","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","volume":"13","author":"BA Nacev","year":"2022","unstructured":"Nacev, B. A., Sanchez-Vega, F., Smith, S. A., et al. (2022). Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 13, 3405.","journal-title":"Nature Communications"},{"key":"10381_CR68","doi-asserted-by":"crossref","unstructured":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. (2010). J Clin Oncol 28, 1247\u20131253.","DOI":"10.1200\/JCO.2009.24.2099"},{"key":"10381_CR69","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","volume":"42","author":"M Debiec-Rychter","year":"2006","unstructured":"Debiec-Rychter, M., Sciot, R., Le Cesne, A., et al. (2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer, 42, 1093\u20131103.","journal-title":"European Journal of Cancer"},{"key":"10381_CR70","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich, M. C., Owzar, K., Corless, C. L., et al. (2008). Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Journal of Clinical Oncology, 26, 5360\u20135367.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR71","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(24)00259-6","volume":"25","author":"D Bertsimas","year":"2024","unstructured":"Bertsimas, D., Margonis, G. A., Sujichantararat, S., et al. (2024). Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: An observational cohort study. The lancet Oncology, 25, 1025\u20131037.","journal-title":"The lancet Oncology"},{"key":"10381_CR72","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/annonc\/mdr127","volume":"23","author":"A Wozniak","year":"2012","unstructured":"Wozniak, A., Rutkowski, P., Piskorz, A., et al. (2012). Prognostic value of KIT\/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology, 23, 353\u2013360.","journal-title":"Annals of Oncology"},{"key":"10381_CR73","doi-asserted-by":"publisher","first-page":"11522","DOI":"10.1200\/JCO.2023.41.16_suppl.11522","volume":"41","author":"JC Trent","year":"2023","unstructured":"Trent, J. C., G\u00f3mez-Peregrina, D., Elliott, A., et al. (2023). Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort. Journal of Clinical Oncology., 41, 11522\u201311522.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR74","doi-asserted-by":"publisher","first-page":"22746","DOI":"10.1073\/pnas.1914542116","volume":"116","author":"Y Pang","year":"2019","unstructured":"Pang, Y., Xie, F., Cao, H., et al. (2019). Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci U S A., 116, 22746\u201322753.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10381_CR75","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.1038\/s41467-024-53821-1","volume":"15","author":"F Xie","year":"2024","unstructured":"Xie, F., Luo, S., Liu, D., et al. (2024). Genomic and transcriptomic landscape of human gastrointestinal stromal tumors. Nature Communications, 15, 9495.","journal-title":"Nature Communications"},{"key":"10381_CR76","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ng.2974","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang, Y., Marino-Enriquez, A., Bennett, R. R., et al. (2014). Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 46, 601\u2013606.","journal-title":"Nature Genetics"},{"key":"10381_CR77","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4143\/crt.2015.015","volume":"48","author":"C Yoo","year":"2016","unstructured":"Yoo, C., Ryu, M. H., Jo, J., Park, I., Ryoo, B. Y., & Kang, Y. K. (2016). Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors. Cancer Research and Treatment, 48, 546\u2013552.","journal-title":"Cancer Research and Treatment"},{"key":"10381_CR78","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless, C. L., Schroeder, A., Griffith, D., et al. (2005). PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. Journal of Clinical Oncology, 23, 5357\u20135364.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR79","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000505407","volume":"87","author":"S Haefliger","year":"2020","unstructured":"Haefliger, S., Marston, K., Juskevicius, D., et al. (2020). Molecular profile of gastrointestinal stromal tumors in sixty-eight patients from a single Swiss institution. Pathobiology, 87, 171\u2013178.","journal-title":"Pathobiology"},{"key":"10381_CR80","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/398570","volume":"2013","author":"PF Salvi","year":"2013","unstructured":"Salvi, P. F., Lorenzon, L., Caterino, S., Antolino, L., Antonelli, M. S., & Balducci, G. (2013). Gastrointestinal stromal tumors associated with neurofibromatosis 1: A single centre experience and systematic review of the literature including 252 cases. International Journal of Surgical Oncology, 2013, Article 398570.","journal-title":"International Journal of Surgical Oncology"},{"key":"10381_CR81","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos, S. A., Pappo, A. S., Killian, J. K., et al. (2016). Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: A report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncology, 2, 922\u2013928.","journal-title":"JAMA Oncology"},{"key":"10381_CR82","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.humpath.2017.01.005","volume":"62","author":"S Huss","year":"2017","unstructured":"Huss, S., Pasternack, H., Ihle, M. A., et al. (2017). Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT\/PDGFRA wild-type GISTs are rare events. Human Pathology, 62, 206\u2013214.","journal-title":"Human Pathology"},{"key":"10381_CR83","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00284","author":"H Fujii","year":"2024","unstructured":"Fujii, H., Hirano, H., Shiraishi, K., et al. (2024). Comprehensive genomic assessment of advanced-stage GI stromal tumors using the Japanese National Center for Cancer Genomics and Advanced Therapeutics database. JCO Precision Oncology. https:\/\/doi.org\/10.1200\/PO.24.00284","journal-title":"JCO Precision Oncology"},{"key":"10381_CR84","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1158\/1078-0432.CCR-14-1677","volume":"20","author":"A Wozniak","year":"2014","unstructured":"Wozniak, A., Rutkowski, P., Sch\u00f6ffski, P., et al. (2014). Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: A European multicenter analysis based on ConticaGIST. Clinical Cancer Research, 20, 6105\u20136116.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR85","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/MOG.0000000000000584","volume":"35","author":"G Mantese","year":"2019","unstructured":"Mantese, G. (2019). Gastrointestinal stromal tumor: Epidemiology, diagnosis, and treatment. Current Opinion in Gastroenterology, 35, 555\u2013559.","journal-title":"Current Opinion in Gastroenterology"},{"key":"10381_CR86","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2011.07.029","volume":"312","author":"M Daniels","year":"2011","unstructured":"Daniels, M., Lurkin, I., Pauli, R., et al. (2011). Spectrum of KIT\/PDGFRA\/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Letters, 312, 43\u201354.","journal-title":"Cancer Letters"},{"key":"10381_CR87","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/modpathol.2015.160","volume":"29","author":"J Lasota","year":"2016","unstructured":"Lasota, J., Felisiak-Golabek, A., Wasag, B., et al. (2016). Frequency and clinicopathologic profile of PIK3CA mutant GISTs: Molecular genetic study of 529 cases. Modern Pathology, 29, 275\u2013282.","journal-title":"Modern Pathology"},{"key":"10381_CR88","doi-asserted-by":"publisher","first-page":"14674","DOI":"10.1038\/ncomms14674","volume":"8","author":"IM Schaefer","year":"2017","unstructured":"Schaefer, I. M., Wang, Y., Liang, C. W., et al. (2017). MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 8, 14674.","journal-title":"Nature Communications"},{"key":"10381_CR89","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1136\/gutjnl-2015-309482","volume":"65","author":"KK Huang","year":"2016","unstructured":"Huang, K. K., McPherson, J. R., Tay, S. T., et al. (2016). SETD2 histone modifier loss in aggressive GI stromal tumours. Gut, 65, 1960\u20131972.","journal-title":"Gut"},{"key":"10381_CR90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009961","volume":"6","author":"JK Killian","year":"2014","unstructured":"Killian, J. K., Miettinen, M., Walker, R. L., et al. (2014). Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Science Translational Medicine, 6, Article 268ra177.","journal-title":"Science Translational Medicine"},{"key":"10381_CR91","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"C Miranda","year":"2012","unstructured":"Miranda, C., Nucifora, M., Molinari, F., et al. (2012). KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clinical Cancer Research, 18, 1769\u20131776.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR92","doi-asserted-by":"crossref","unstructured":"Sharma, A. K, de la Torre, J., N.S, IJ, et al. (2021). Location of gastrointestinal stromal tumor (GIST) in the stomach predicts tumor mutation profile and drug sensitivity. Clin Cancer Res 27, 5334\u20135342.","DOI":"10.1158\/1078-0432.CCR-21-1221"},{"key":"10381_CR93","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/gcc.2870010208","volume":"1","author":"G Stenman","year":"1989","unstructured":"Stenman, G., Eriksson, A., & Claesson-Welsh, L. (1989). Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene. Genes, Chromosomes & Cancer, 1, 155\u2013158.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR94","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2018.06.016","volume":"191","author":"LR Klug","year":"2018","unstructured":"Klug, L. R., Kent, J. D., & Heinrich, M. C. (2018). Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases. Pharmacology & Therapeutics, 191, 123\u2013134.","journal-title":"Pharmacology & Therapeutics"},{"key":"10381_CR95","first-page":"8118","volume":"61","author":"BP Rubin","year":"2001","unstructured":"Rubin, B. P., Singer, S., Tsao, C., et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research, 61, 8118\u20138121.","journal-title":"Cancer Research"},{"key":"10381_CR96","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2559.2008.02977.x","volume":"53","author":"J Lasota","year":"2008","unstructured":"Lasota, J., & Miettinen, M. (2008). Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology, 53, 245\u2013266.","journal-title":"Histopathology"},{"key":"10381_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020194","author":"I Br\u010di\u0107","year":"2021","unstructured":"Br\u010di\u0107, I., Argyropoulos, A., & Liegl-Atzwanger, B. (2021). Update on molecular genetics of gastrointestinal stromal tumors. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics11020194","journal-title":"Diagnostics"},{"key":"10381_CR98","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/labinvest.3700122","volume":"84","author":"J Lasota","year":"2004","unstructured":"Lasota, J., Dansonka-Mieszkowska, A., Sobin, L. H., & Miettinen, M. (2004). A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Laboratory Investigation, 84, 874\u2013883.","journal-title":"Laboratory Investigation"},{"key":"10381_CR99","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/modpathol.2008.2","volume":"21","author":"J Lasota","year":"2008","unstructured":"Lasota, J., Corless, C. L., Heinrich, M. C., et al. (2008). Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases. Modern Pathology, 21, 476\u2013484.","journal-title":"Modern Pathology"},{"key":"10381_CR100","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011). Gastrointestinal stromal tumours: Origin and molecular oncology. Nature Reviews Cancer, 11, 865\u2013878.","journal-title":"Nature Reviews Cancer"},{"key":"10381_CR101","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","volume":"19","author":"WW Chan","year":"2011","unstructured":"Chan, W. W., Wise, S. C., Kaufman, M. D., et al. (2011). Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell, 19, 556\u2013568.","journal-title":"Cancer Cell"},{"key":"10381_CR102","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1073\/pnas.0812413106","volume":"106","author":"KS Gajiwala","year":"2009","unstructured":"Gajiwala, K. S., Wu, J. C., Christensen, J., et al. (2009). KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A., 106, 1542\u20131547.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10381_CR103","doi-asserted-by":"crossref","unstructured":"Lasota, J., Wozniak, A., Sarlomo-Rikala, M., et al.\u00a0(2000) Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157: 1091\u20131095.","DOI":"10.1016\/S0002-9440(10)64623-8"},{"key":"10381_CR104","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2014.57.4970","volume":"33","author":"H Joensuu","year":"2015","unstructured":"Joensuu, H., Rutkowski, P., Nishida, T., et al. (2015). KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. Journal of Clinical Oncology, 33, 634\u2013642.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR105","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1038\/sj.onc.1210558","volume":"26","author":"S Bauer","year":"2007","unstructured":"Bauer, S., Duensing, A., Demetri, G. D., & Fletcher, J. A. (2007). KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase\/AKT is a crucial survival pathway. Oncogene, 26, 7560\u20137568.","journal-title":"Oncogene"},{"key":"10381_CR106","doi-asserted-by":"publisher","first-page":"E8448","DOI":"10.1073\/pnas.1711449114","volume":"114","author":"B Bosbach","year":"2017","unstructured":"Bosbach, B., Rossi, F., Yozgat, Y., et al. (2017). Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proc Natl Acad Sci U S A., 114, E8448-e8457.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10381_CR107","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-14-0985","volume":"5","author":"L Ran","year":"2015","unstructured":"Ran, L., Sirota, I., Cao, Z., et al. (2015). Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discovery, 5, 304\u2013315.","journal-title":"Cancer Discovery"},{"key":"10381_CR108","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2159-8290.CD-17-0468","volume":"8","author":"L Ran","year":"2018","unstructured":"Ran, L., Chen, Y., Sher, J., et al. (2018). FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor. Cancer Discovery, 8, 234\u2013251.","journal-title":"Cancer Discovery"},{"key":"10381_CR109","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1158\/0008-5472.CAN-16-3510","volume":"77","author":"L Ran","year":"2017","unstructured":"Ran, L., Murphy, D., Sher, J., et al. (2017). ETV1-positive cells give rise to BRAF(V600E) -mutant gastrointestinal stromal tumors. Cancer Research, 77, 3758\u20133765.","journal-title":"Cancer Research"},{"key":"10381_CR110","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.humpath.2006.07.002","volume":"37","author":"K Kawanowa","year":"2006","unstructured":"Kawanowa, K., Sakuma, Y., Sakurai, S., et al. (2006). High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathology, 37, 1527\u20131535.","journal-title":"Human Pathology"},{"key":"10381_CR111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/01.pas.0000213307.05811.f0","volume":"31","author":"A Agaimy","year":"2007","unstructured":"Agaimy, A., W\u00fcnsch, P. H., Hofstaedter, F., et al. (2007). Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. American Journal of Surgical Pathology, 31, 113\u2013120.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR112","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.humpath.2013.07.020","volume":"44","author":"T Mikami","year":"2013","unstructured":"Mikami, T., Nemoto, Y., Numata, Y., et al. (2013). Small gastrointestinal stromal tumor in the stomach: Identification of precursor for clinical gastrointestinal stromal tumor using c-kit and \u03b1-smooth muscle actin expression. Human Pathology, 44, 2628\u20132635.","journal-title":"Human Pathology"},{"key":"10381_CR113","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s12885-015-1872-y","volume":"15","author":"MG Belinsky","year":"2015","unstructured":"Belinsky, M. G., Rink, L., Cai, K. Q., et al. (2015). Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer, 15, 887.","journal-title":"BMC Cancer"},{"key":"10381_CR114","first-page":"3899","volume":"60","author":"W El-Rifai","year":"2000","unstructured":"El-Rifai, W., Sarlomo-Rikala, M., Andersson, L. C., Knuutila, S., & Miettinen, M. (2000). DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Research, 60, 3899\u20133903.","journal-title":"Cancer Research"},{"key":"10381_CR115","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/hupa.2002.32216","volume":"33","author":"B Gunawan","year":"2002","unstructured":"Gunawan, B., Bergmann, F., H\u00f6er, J., et al. (2002). Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Human Pathology, 33, 316\u2013321.","journal-title":"Human Pathology"},{"key":"10381_CR116","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.humpath.2013.05.027","volume":"45","author":"IM Schaefer","year":"2014","unstructured":"Schaefer, I. M., Delfs, C., Cameron, S., et al. (2014). Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors. Human Pathology, 45, 85\u201397.","journal-title":"Human Pathology"},{"key":"10381_CR117","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<633::AID-IJC6>3.0.CO;2-5","volume":"85","author":"NG Kim","year":"2000","unstructured":"Kim, N. G., Kim, J. J., Ahn, J. Y., et al. (2000). Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. International Journal of Cancer, 85, 633\u2013638.","journal-title":"International Journal of Cancer"},{"key":"10381_CR118","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1038\/s41467-025-58678-6","volume":"16","author":"A Soupir","year":"2025","unstructured":"Soupir, A., Ospina, O. E., Hampton, O., et al. (2025). Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes. Nature Communications, 16, 4206.","journal-title":"Nature Communications"},{"key":"10381_CR119","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/1078-0432.638.11.2","volume":"11","author":"R Schneider-Stock","year":"2005","unstructured":"Schneider-Stock, R., Boltze, C., Lasota, J., et al. (2005). Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study. Clinical Cancer Research, 11, 638\u2013645.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13569-019-0112-7","volume":"9","author":"MC Heinrich","year":"2019","unstructured":"Heinrich, M. C., Patterson, J., Beadling, C., et al. (2019). Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clinical Sarcoma Research, 9, 3.","journal-title":"Clinical Sarcoma Research"},{"key":"10381_CR121","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/gcc.20408","volume":"46","author":"A Wozniak","year":"2007","unstructured":"Wozniak, A., Sciot, R., Guillou, L., et al. (2007). Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes, Chromosomes & Cancer, 46, 261\u2013276.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.humpath.2020.10.010","volume":"107","author":"CW Liang","year":"2021","unstructured":"Liang, C. W., Yang, C. Y., Flavin, R., et al. (2021). Loss of SFRP1 expression is a key progression event in gastrointestinal stromal tumor pathogenesis. Human Pathology, 107, 69\u201379.","journal-title":"Human Pathology"},{"key":"10381_CR123","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00014","author":"AM Burgoyne","year":"2017","unstructured":"Burgoyne, A. M., De Siena, M., Alkhuziem, M., et al. (2017). Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and Notch pathway mutations. JCO Precision Oncology. https:\/\/doi.org\/10.1200\/PO.17.00014","journal-title":"JCO Precision Oncology"},{"key":"10381_CR124","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"KA Janeway","year":"2011","unstructured":"Janeway, K. A., Kim, S. Y., Lodish, M., et al. (2011). Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A., 108, 314\u2013318.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10381_CR125","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1097\/PAS.0b013e3182260752","volume":"35","author":"M Miettinen","year":"2011","unstructured":"Miettinen, M., Wang, Z. F., Sarlomo-Rikala, M., Osuch, C., Rutkowski, P., & Lasota, J. (2011). Succinate dehydrogenase-deficient GISTs: A clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. American Journal of Surgical Pathology, 35, 1712\u20131721.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR126","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/ejhg.2013.80","volume":"22","author":"MA Pantaleo","year":"2014","unstructured":"Pantaleo, M. A., Astolfi, A., Urbini, M., et al. (2014). Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT\/PDGFRA wild-type GIST. European Journal of Human Genetics, 22, 32\u201339.","journal-title":"European Journal of Human Genetics"},{"key":"10381_CR127","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1365-2559.2012.04300.x","volume":"61","author":"LA Doyle","year":"2012","unstructured":"Doyle, L. A., Nelson, D., Heinrich, M. C., Corless, C. L., & Hornick, J. L. (2012). Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: A comprehensive genotype-phenotype correlation study. Histopathology, 61, 801\u2013809.","journal-title":"Histopathology"},{"key":"10381_CR128","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1530\/ERC-14-0254","volume":"21","author":"F Haller","year":"2014","unstructured":"Haller, F., Moskalev, E. A., Faucz, F. R., et al. (2014). Aberrant DNA hypermethylation of SDHC: A novel mechanism of tumor development in Carney triad. Endocrine-Related Cancer, 21, 567\u2013577.","journal-title":"Endocrine-Related Cancer"},{"key":"10381_CR129","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","volume":"3","author":"JK Killian","year":"2013","unstructured":"Killian, J. K., Kim, S. Y., Miettinen, M., et al. (2013). Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discovery, 3, 648\u2013657.","journal-title":"Cancer Discovery"},{"key":"10381_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030646","author":"A Schipani","year":"2023","unstructured":"Schipani, A., Nannini, M., Astolfi, A., & Pantaleo, M. A. (2023). SDHA germline mutations in SDH-deficient GISTs: A current update. Genes. https:\/\/doi.org\/10.3390\/genes14030646","journal-title":"Genes"},{"key":"10381_CR131","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/PAS.0b013e3182671178","volume":"37","author":"M Miettinen","year":"2013","unstructured":"Miettinen, M., Killian, J. K., Wang, Z. F., et al. (2013). Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. American Journal of Surgical Pathology, 37, 234\u2013240.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR132","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/jnci\/djr130","volume":"103","author":"MA Pantaleo","year":"2011","unstructured":"Pantaleo, M. A., Astolfi, A., Indio, V., et al. (2011). SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. Journal of the National Cancer Institute, 103, 983\u2013987.","journal-title":"Journal of the National Cancer Institute"},{"key":"10381_CR133","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/gim.2014.115","volume":"17","author":"MA Pantaleo","year":"2015","unstructured":"Pantaleo, M. A., Lolli, C., Nannini, M., et al. (2015). Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genetics in Medicine, 17, 391\u2013395.","journal-title":"Genetics in Medicine"},{"key":"10381_CR134","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/cas.16058","volume":"115","author":"T Nishida","year":"2024","unstructured":"Nishida, T., Naito, Y., Takahashi, T., et al. (2024). Molecular and clinicopathological features of KIT\/PDGFRA wild-type gastrointestinal stromal tumors. Cancer Science, 115, 894\u2013904.","journal-title":"Cancer Science"},{"key":"10381_CR135","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/ajmg.10235","volume":"108","author":"JA Carney","year":"2002","unstructured":"Carney, J. A., & Stratakis, C. A. (2002). Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad. American Journal of Medical Genetics, 108, 132\u2013139.","journal-title":"American Journal of Medical Genetics"},{"key":"10381_CR136","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJM197706302962609","volume":"296","author":"JA Carney","year":"1977","unstructured":"Carney, J. A., Sheps, S. G., Go, V. L., & Gordon, H. (1977). The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. New England Journal of Medicine, 296, 1517\u20131518.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR137","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMc071191","volume":"357","author":"SR McWhinney","year":"2007","unstructured":"McWhinney, S. R., Pasini, B., & Stratakis, C. A. (2007). Familial gastrointestinal stromal tumors and germ-line mutations. New England Journal of Medicine, 357, 1054\u20131056.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR138","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1210\/jc.2007-0797","volume":"92","author":"L Matyakhina","year":"2007","unstructured":"Matyakhina, L., Bei, T. A., McWhinney, S. R., et al. (2007). Genetics of carney triad: Recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. Journal of Clinical Endocrinology and Metabolism, 92, 2938\u20132943.","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10381_CR139","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak, M. A., Armour, S. M., MacKenzie, E. D., et al. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77\u201385.","journal-title":"Cancer Cell"},{"key":"10381_CR140","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ccr.2013.05.015","volume":"23","author":"M Yang","year":"2013","unstructured":"Yang, M., & Pollard, P. J. (2013). Succinate: A new epigenetic hacker. Cancer Cell, 23, 709\u2013711.","journal-title":"Cancer Cell"},{"key":"10381_CR141","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/modpathol.2013.86","volume":"26","author":"EF Mason","year":"2013","unstructured":"Mason, E. F., & Hornick, J. L. (2013). Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: Implications for mechanisms of tumorigenesis. Modern Pathology, 26, 1492\u20131497.","journal-title":"Modern Pathology"},{"key":"10381_CR142","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","volume":"30","author":"A Morin","year":"2020","unstructured":"Morin, A., Goncalves, J., Moog, S., et al. (2020). TET-mediated hypermethylation primes SDH-deficient cells for HIF2\u03b1-driven mesenchymal transition. Cell Reports, 30, 4551-4566.e4557.","journal-title":"Cell Reports"},{"key":"10381_CR143","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-019-1668-3","volume":"575","author":"WA Flavahan","year":"2019","unstructured":"Flavahan, W. A., Drier, Y., Johnstone, S. E., et al. (2019). Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature, 575, 229\u2013233.","journal-title":"Nature"},{"key":"10381_CR144","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cam4.57","volume":"2","author":"C Beadling","year":"2013","unstructured":"Beadling, C., Patterson, J., Justusson, E., et al. (2013). Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA. Cancer Medicine, 2, 21\u201331.","journal-title":"Cancer Medicine"},{"key":"10381_CR145","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/gcc.22023","volume":"52","author":"MG Belinsky","year":"2013","unstructured":"Belinsky, M. G., Rink, L., Flieder, D. B., et al. (2013). Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes, Chromosomes & Cancer, 52, 214\u2013224.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR146","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1002\/ijc.24595","volume":"125","author":"MA Pantaleo","year":"2009","unstructured":"Pantaleo, M. A., Astolfi, A., Di Battista, M., et al. (2009). Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target. International Journal of Cancer, 125, 2991\u20132994.","journal-title":"International Journal of Cancer"},{"key":"10381_CR147","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2217\/epi-2016-0030","volume":"8","author":"MA Pantaleo","year":"2016","unstructured":"Pantaleo, M. A., Ravegnini, G., Astolfi, A., et al. (2016). Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 8, 1347\u20131366.","journal-title":"Epigenomics"},{"key":"10381_CR148","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1073\/pnas.0803383105","volume":"105","author":"C Tarn","year":"2008","unstructured":"Tarn, C., Rink, L., Merkel, E., et al. (2008). Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A., 105, 8387\u20138392.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10381_CR149","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.1158\/0008-5472.CAN-07-1938","volume":"67","author":"KA Janeway","year":"2007","unstructured":"Janeway, K. A., Liegl, B., Harlow, A., et al. (2007). Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Research, 67, 9084\u20139088.","journal-title":"Cancer Research"},{"key":"10381_CR150","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00497","volume":"9","author":"CM Cicala","year":"2025","unstructured":"Cicala, C. M., Matito, J., Quindos, M., et al. (2025). Targeted next-generation sequencing in succinate dehydrogenase-deficient GI stromal tumor identifies actionable alterations in the PI3K\/mTOR pathway. JCO Precision Oncology, 9, Article e2400497.","journal-title":"JCO Precision Oncology"},{"key":"10381_CR151","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1078-0432.CCR-16-0152","volume":"23","author":"D Gasparotto","year":"2017","unstructured":"Gasparotto, D., Rossi, S., Polano, M., et al. (2017). Quadruple-negative GIST is a sentinel for unrecognized neurofibromatosis type 1 syndrome. Clinical Cancer Research, 23, 273\u2013282.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR152","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/01.pas.0000176433.81079.bd","volume":"30","author":"M Miettinen","year":"2006","unstructured":"Miettinen, M., Fetsch, J. F., Sobin, L. H., & Lasota, J. (2006). Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular genetic study of 45 cases. American Journal of Surgical Pathology, 30, 90\u201396.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR153","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","volume":"62","author":"D Viskochil","year":"1990","unstructured":"Viskochil, D., Buchberg, A. M., Xu, G., et al. (1990). Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell, 62, 187\u2013192.","journal-title":"Cell"},{"key":"10381_CR154","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner, N., & Miller, S. J. (2015). A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. Nature Reviews Cancer, 15, 290\u2013301.","journal-title":"Nature Reviews Cancer"},{"key":"10381_CR155","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-08-0086","volume":"14","author":"C Mussi","year":"2008","unstructured":"Mussi, C., Schildhaus, H. U., Gronchi, A., Wardelmann, E., & Hohenberger, P. (2008). Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clinical Cancer Research, 14, 4550\u20134555.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR156","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","volume":"41","author":"J Mo","year":"2022","unstructured":"Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022). Neurofibromin and suppression of tumorigenesis: Beyond the GAP. Oncogene, 41, 1235\u20131251.","journal-title":"Oncogene"},{"key":"10381_CR157","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/356713a0","volume":"356","author":"TN Basu","year":"1992","unstructured":"Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., & Downward, J. (1992). Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature, 356, 713\u2013715.","journal-title":"Nature"},{"key":"10381_CR158","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/hmg\/ddl016","volume":"15","author":"O Maertens","year":"2006","unstructured":"Maertens, O., Prenen, H., Debiec-Rychter, M., et al. (2006). Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Human Molecular Genetics, 15, 1015\u20131023.","journal-title":"Human Molecular Genetics"},{"key":"10381_CR159","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0945","volume":"4","author":"JP Landry","year":"2021","unstructured":"Landry, J. P., Schertz, K. L., Chiang, Y. J., et al. (2021). Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Network Open, 4, Article e210945.","journal-title":"JAMA Network Open"},{"key":"10381_CR160","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N","volume":"79","author":"ME Z\u00f6ller","year":"1997","unstructured":"Z\u00f6ller, M. E., Rembeck, B., Od\u00e9n, A., Samuelsson, M., & Angervall, L. (1997). Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer, 79, 2125\u20132131.","journal-title":"Cancer"},{"key":"10381_CR161","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1097\/01.pas.0000159775.77912.15","volume":"29","author":"J Andersson","year":"2005","unstructured":"Andersson, J., Sihto, H., Meis-Kindblom, J. M., Joensuu, H., Nupponen, N., & Kindblom, L. G. (2005). NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. American Journal of Surgical Pathology, 29, 1170\u20131176.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR162","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/modpathol.3800334","volume":"18","author":"RK Yantiss","year":"2005","unstructured":"Yantiss, R. K., Rosenberg, A. E., Sarran, L., Besmer, P., & Antonescu, C. R. (2005). Multiple gastrointestinal stromal tumors in type I neurofibromatosis: A pathologic and molecular study. Modern Pathology, 18, 475\u2013484.","journal-title":"Modern Pathology"},{"key":"10381_CR163","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamasurg.2016.5047","volume":"152","author":"KE Fero","year":"2017","unstructured":"Fero, K. E., Coe, T. M., Fanta, P. T., Tang, C. M., Murphy, J. D., & Sicklick, J. K. (2017). Surgical management of adolescents and young adults with gastrointestinal stromal tumors: A US population-based analysis. JAMA Surgery, 152, 443\u2013451.","journal-title":"JAMA Surgery"},{"key":"10381_CR164","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/pin.12431","volume":"66","author":"R Wada","year":"2016","unstructured":"Wada, R., Arai, H., Kure, S., Peng, W. X., & Naito, Z. (2016). \u201cWild type\u201d GIST: Clinicopathological features and clinical practice. Pathology International, 66, 431\u2013437.","journal-title":"Pathology International"},{"key":"10381_CR165","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/modpathol.2013.89","volume":"26","author":"J Lasota","year":"2013","unstructured":"Lasota, J., Xi, L., Coates, T., et al. (2013). No KRAS mutations found in gastrointestinal stromal tumors (GISTs): Molecular genetic study of 514 cases. Modern Pathology, 26, 1488\u20131491.","journal-title":"Modern Pathology"},{"key":"10381_CR166","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1136\/jcp.2009.064550","volume":"62","author":"A Agaimy","year":"2009","unstructured":"Agaimy, A., Terracciano, L. M., Dirnhofer, S., et al. (2009). V600E BRAF mutations are alternative early molecular events in a subset of KIT\/PDGFRA wild-type gastrointestinal stromal tumours. Journal of Clinical Pathology, 62, 613\u2013616.","journal-title":"Journal of Clinical Pathology"},{"key":"10381_CR167","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1200\/JCO.2013.48.7488","volume":"33","author":"C Serrano","year":"2015","unstructured":"Serrano, C., Wang, Y., Mari\u00f1o-Enr\u00edquez, A., et al. (2015). KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors: Relevance of concomitant phosphatidylinositol 3-kinase\/AKT dysregulation. Journal of Clinical Oncology, 33, e93-96.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR168","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/gcc.20589","volume":"47","author":"NP Agaram","year":"2008","unstructured":"Agaram, N. P., Wong, G. C., Guo, T., et al. (2008). Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes, Chromosomes & Cancer, 47, 853\u2013859.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR169","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1309\/AJCPPCKGA2QGBJ1R","volume":"133","author":"I Hostein","year":"2010","unstructured":"Hostein, I., Faur, N., Primois, C., et al. (2010). BRAF mutation status in gastrointestinal stromal tumors. American Journal of Clinical Pathology, 133, 141\u2013148.","journal-title":"American Journal of Clinical Pathology"},{"key":"10381_CR170","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cam4.325","volume":"4","author":"MA Pantaleo","year":"2015","unstructured":"Pantaleo, M. A., Nannini, M., Corless, C. L., & Heinrich, M. C. (2015). Quadruple wild-type (WT) GIST: Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Medicine, 4, 101\u2013103.","journal-title":"Cancer Medicine"},{"key":"10381_CR171","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/1471-2407-14-685","volume":"14","author":"M Nannini","year":"2014","unstructured":"Nannini, M., Astolfi, A., Urbini, M., et al. (2014). Integrated genomic study of quadruple-WT GIST (KIT\/PDGFRA\/SDH\/RAS pathway wild-type GIST). BMC Cancer, 14, 685.","journal-title":"BMC Cancer"},{"key":"10381_CR172","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/path.4677","volume":"238","author":"M Brenca","year":"2016","unstructured":"Brenca, M., Rossi, S., Polano, M., et al. (2016). Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. The Journal of Pathology, 238, 543\u2013549.","journal-title":"The Journal of Pathology"},{"key":"10381_CR173","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1541-7786.MCR-16-0376","volume":"15","author":"MA Pantaleo","year":"2017","unstructured":"Pantaleo, M. A., Urbini, M., Indio, V., et al. (2017). Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Molecular Cancer Research, 15, 553\u2013562.","journal-title":"Molecular Cancer Research"},{"key":"10381_CR174","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112659","author":"JH Lee","year":"2022","unstructured":"Lee, J. H., Shin, S. J., Choe, E. A., et al. (2022). Tropomyosin-related kinase fusions in gastrointestinal stromal tumors. Cancers. https:\/\/doi.org\/10.3390\/cancers14112659","journal-title":"Cancers"},{"key":"10381_CR175","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi, E., Chmielecki, J., Tang, C. M., et al. (2016). FGFR1 and NTRK3 actionable alterations in \u201cwild-type\u201d gastrointestinal stromal tumors. Journal of Translational Medicine, 14, 339.","journal-title":"Journal of Translational Medicine"},{"key":"10381_CR176","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/gcc.22753","volume":"58","author":"M Urbini","year":"2019","unstructured":"Urbini, M., Indio, V., Tarantino, G., et al. (2019). Gain of FGF4 is a frequent event in KIT\/PDGFRA\/SDH\/RAS-P WT GIST. Genes, Chromosomes & Cancer, 58, 636\u2013642.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR177","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96, 925\u2013932.","journal-title":"Blood"},{"key":"10381_CR178","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","volume":"344","author":"H Joensuu","year":"2001","unstructured":"Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., et al. (2001). Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New England Journal of Medicine, 344, 1052\u20131056.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR179","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/00000658-199201000-00010","volume":"215","author":"EH Ng","year":"1992","unstructured":"Ng, E. H., Pollock, R. E., Munsell, M. F., Atkinson, E. N., & Romsdahl, M. M. (1992). Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Annals of Surgery, 215, 68\u201377.","journal-title":"Annals of Surgery"},{"key":"10381_CR180","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1245\/s10434-006-9177-7","volume":"14","author":"JS Gold","year":"2007","unstructured":"Gold, J. S., van der Zwan, S. M., G\u00f6nen, M., et al. (2007). Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Annals of Surgical Oncology, 14, 134\u2013142.","journal-title":"Annals of Surgical Oncology"},{"key":"10381_CR181","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/83.13.926","volume":"83","author":"M Zalupski","year":"1991","unstructured":"Zalupski, M., Metch, B., Balcerzak, S., et al. (1991). Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group study. Journal of the National Cancer Institute, 83, 926\u2013932.","journal-title":"Journal of the National Cancer Institute"},{"key":"10381_CR182","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1081\/CNV-120002485","volume":"20","author":"JH Edmonson","year":"2002","unstructured":"Edmonson, J. H., Marks, R. S., Buckner, J. C., & Mahoney, M. R. (2002). Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Investigation, 20, 605\u2013612.","journal-title":"Cancer Investigation"},{"key":"10381_CR183","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1634\/theoncologist.7-6-531","volume":"7","author":"DP Ryan","year":"2002","unstructured":"Ryan, D. P., Puchalski, T., Supko, J. G., et al. (2002). A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. The Oncologist, 7, 531\u2013538.","journal-title":"The Oncologist"},{"key":"10381_CR184","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/cncr.11875","volume":"98","author":"JC Trent","year":"2003","unstructured":"Trent, J. C., Beach, J., Burgess, M. A., et al. (2003). A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 98, 2693\u20132699.","journal-title":"Cancer"},{"key":"10381_CR185","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke, C. D., Rankin, C., Demetri, G. D., et al. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology, 26, 626\u2013632.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR186","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke, C. D., Demetri, G. D., von Mehren, M., et al. (2008). Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Journal of Clinical Oncology, 26, 620\u2013625.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR187","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"PG Casali","year":"2017","unstructured":"Casali, P. G., Zalcberg, J., Le Cesne, A., et al. (2017). Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: Long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. Journal of Clinical Oncology, 35, 1713\u20131720.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR188","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"MC Heinrich","year":"2017","unstructured":"Heinrich, M. C., Rankin, C., Blanke, C. D., et al. (2017). Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: Analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncology, 3, 944\u2013952.","journal-title":"JAMA Oncology"},{"key":"10381_CR189","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij, J., Casali, P. G., Zalcberg, J., et al. (2004). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet, 364, 1127\u20131134.","journal-title":"Lancet"},{"key":"10381_CR190","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","volume":"358","author":"AT van Oosterom","year":"2001","unstructured":"van Oosterom, A. T., Judson, I., Verweij, J., et al. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet, 358, 1421\u20131423.","journal-title":"Lancet"},{"key":"10381_CR191","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.pas.0000146010.92933.de","volume":"29","author":"M Miettinen","year":"2005","unstructured":"Miettinen, M., Sobin, L. H., & Lasota, J. (2005). Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. American Journal of Surgical Pathology, 29, 52\u201368.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.535","author":"JY Blay","year":"2025","unstructured":"Blay, J. Y., Devin, Q., Toulmonde, M., et al. (2025). Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: Exploratory long-term follow-up of the BFR14 trial. Annals of Oncology. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.535","journal-title":"Annals of Oncology"},{"key":"10381_CR193","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","volume":"18","author":"PA Cassier","year":"2012","unstructured":"Cassier, P. A., Fumagalli, E., Rutkowski, P., et al. (2012). Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clinical Cancer Research, 18, 4458\u20134464.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR194","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2017.02.007","volume":"76","author":"S Farag","year":"2017","unstructured":"Farag, S., Somaiah, N., Choi, H., et al. (2017). Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. European Journal of Cancer, 76, 76\u201383.","journal-title":"European Journal of Cancer"},{"key":"10381_CR195","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1349-7006.2008.00727.x","volume":"99","author":"T Nishida","year":"2008","unstructured":"Nishida, T., Kanda, T., Nishitani, A., et al. (2008). Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Science, 99, 799\u2013804.","journal-title":"Cancer Science"},{"key":"10381_CR196","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","volume":"120","author":"C Serrano","year":"2019","unstructured":"Serrano, C., Mari\u00f1o-Enr\u00edquez, A., Tao, D. L., et al. (2019). Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer, 120, 612\u2013620.","journal-title":"British Journal of Cancer"},{"key":"10381_CR197","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","volume":"128","author":"M Debiec-Rychter","year":"2005","unstructured":"Debiec-Rychter, M., Cools, J., Dumez, H., et al. (2005). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology, 128, 270\u2013279.","journal-title":"Gastroenterology"},{"key":"10381_CR198","doi-asserted-by":"publisher","first-page":"e22520","DOI":"10.1200\/JCO.2016.34.15_suppl.e22520","volume":"34","author":"B Li","year":"2016","unstructured":"Li, B., Garcia, C. S., Marino-Enriquez, A., et al. (2016). Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST. Journal of Clinical Oncology, 34, e22520.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR199","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1535-7163.MCT-18-1224","volume":"18","author":"T M\u00fchlenberg","year":"2019","unstructured":"M\u00fchlenberg, T., Ketzer, J., Heinrich, M. C., et al. (2019). KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1\/2 inhibition as salvage strategy. Molecular Cancer Therapeutics, 18, 1985\u20131996.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10381_CR200","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/0008-5472.CAN-14-2564","volume":"75","author":"NA Cohen","year":"2015","unstructured":"Cohen, N. A., Zeng, S., Seifert, A. M., et al. (2015). Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors. Cancer Research, 75, 2061\u20132070.","journal-title":"Cancer Research"},{"key":"10381_CR201","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","volume":"5","author":"F Li","year":"2015","unstructured":"Li, F., Huynh, H., Li, X., et al. (2015). FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discovery, 5, 438\u2013451.","journal-title":"Cancer Discovery"},{"key":"10381_CR202","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/0008-5472.CAN-14-0573","volume":"75","author":"N Javidi-Sharifi","year":"2015","unstructured":"Javidi-Sharifi, N., Traer, E., Martinez, J., et al. (2015). Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Research, 75, 880\u2013891.","journal-title":"Cancer Research"},{"key":"10381_CR203","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2559.2005.02179.x","volume":"47","author":"P Pauwels","year":"2005","unstructured":"Pauwels, P., Debiec-Rychter, M., Stul, M., De Wever, I., Van Oosterom, A. T., & Sciot, R. (2005). Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: A potential diagnostic pitfall. Histopathology, 47, 41\u201347.","journal-title":"Histopathology"},{"key":"10381_CR204","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12253-011-9362-2","volume":"17","author":"M D\u00edaz Delgado","year":"2011","unstructured":"D\u00edaz Delgado, M., Hern\u00e1ndez Amate, A., Pereira Gallardo, S., Jaramillo, S., Virizuela Echaburu, J. A., & Gonz\u00e1lez-C\u00e1mpora, R. J. (2011). Gastrointestinal stromal tumors: Morphological, immunohistochemical and molecular changes associated with kinase inhibitor therapy. Pathology Oncology Research, 17, 455\u2013461.","journal-title":"Pathology Oncology Research"},{"key":"10381_CR205","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel, D. B., Laird, A. D., Xin, X., et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship. Clinical Cancer Research, 9, 327\u2013337.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR206","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich, M. C., Maki, R. G., Corless, C. L., et al. (2008). Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Journal of Clinical Oncology, 26, 5352\u20135359.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR207","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12885-016-2051-5","volume":"16","author":"P Reichardt","year":"2016","unstructured":"Reichardt, P., Demetri, G. D., Gelderblom, H., et al. (2016). Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer, 16, 22.","journal-title":"BMC Cancer"},{"key":"10381_CR208","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm, S. M., Dumas, J., Adnane, L., et al. (2011). Regorafenib (BAY 73\u20134506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 129, 245\u2013255.","journal-title":"International Journal of Cancer"},{"key":"10381_CR209","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri, G. D., Reichardt, P., Kang, Y. K., et al. (2013). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381, 295\u2013302.","journal-title":"Lancet"},{"key":"10381_CR210","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1200\/jco.2016.34.4_suppl.156","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri, G. D., Reichardt, P., Kang, Y.-K., et al. (2016). Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology., 34, 156\u2013156.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR211","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"BD Smith","year":"2019","unstructured":"Smith, B. D., Kaufman, M. D., Lu, W. P., et al. (2019). Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell, 35, 738-751.e739.","journal-title":"Cancer Cell"},{"key":"10381_CR212","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. (2020). Ripretinib: First approval. Drugs, 80, 1133\u20131138.","journal-title":"Drugs"},{"key":"10381_CR213","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay, J. Y., Serrano, C., Heinrich, M. C., et al. (2020). Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial. The lancet Oncology, 21, 923\u2013934.","journal-title":"The lancet Oncology"},{"key":"10381_CR214","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.1158\/1078-0432.CCR-19-2150","volume":"25","author":"C Serrano","year":"2019","unstructured":"Serrano, C., Leal, A., Kuang, Y., et al. (2019). Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors. Clinical Cancer Research, 25, 7287\u20137293.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR215","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672500","volume":"11","author":"S Bauer","year":"2021","unstructured":"Bauer, S., George, S., von Mehren, M., & Heinrich, M. C. (2021). Early and next-generation KIT\/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor. Frontiers in Oncology, 11, Article 672500.","journal-title":"Frontiers in Oncology"},{"key":"10381_CR216","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.23.01197","volume":"42","author":"T M\u00fchlenberg","year":"2024","unstructured":"M\u00fchlenberg, T., Falkenhorst, J., Schulz, T., et al. (2024). KIT ATP-binding pocket\/activation loop mutations in GI stromal tumor: Emerging mechanisms of kinase inhibitor escape. Journal of Clinical Oncology., 42, 1439\u20131449.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR217","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11523-017-0490-9","volume":"12","author":"C Serrano","year":"2017","unstructured":"Serrano, C., George, S., Valverde, C., et al. (2017). Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors. Targeted Oncology, 12, 277\u2013288.","journal-title":"Targeted Oncology"},{"key":"10381_CR218","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1158\/1078-0432.CCR-09-1315","volume":"15","author":"T Guo","year":"2009","unstructured":"Guo, T., Hajdu, M., Agaram, N. P., et al. (2009). Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: An in vitro mutagenesis screen for drug resistance. Clinical Cancer Research, 15, 6862\u20136870.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR219","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10147-008-0822-y","volume":"14","author":"T Nishida","year":"2009","unstructured":"Nishida, T., Takahashi, T., Nishitani, A., et al. (2009). Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. International Journal of Clinical Oncology, 14, 143\u2013149.","journal-title":"International Journal of Clinical Oncology"},{"key":"10381_CR220","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10120-025-01639-1","volume":"28","author":"K Kawabata","year":"2025","unstructured":"Kawabata, K., Takahashi, T., Nishida, T., et al. (2025). Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors. Gastric Cancer, 28, 899\u2013910.","journal-title":"Gastric Cancer"},{"key":"10381_CR221","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","volume":"40","author":"S Bauer","year":"2022","unstructured":"Bauer, S., Jones, R. L., Blay, J. Y., et al. (2022). Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): A randomized, open-label, phase III trial. Journal of Clinical Oncology, 40, 3918\u20133928.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR222","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-023-02734-5","volume":"30","author":"MC Heinrich","year":"2024","unstructured":"Heinrich, M. C., Jones, R. L., George, S., et al. (2024). Ripretinib versus sunitinib in gastrointestinal stromal tumor: CtDNA biomarker analysis of the phase 3 INTRIGUE trial. Nature Medicine, 30, 498\u2013506.","journal-title":"Nature Medicine"},{"key":"10381_CR223","doi-asserted-by":"publisher","first-page":"44121","DOI":"10.18632\/oncotarget.17310","volume":"8","author":"CN Yeh","year":"2017","unstructured":"Yeh, C. N., Chen, M. H., Chen, Y. Y., et al. (2017). A phase II trial of regorafenib in patients with metastatic and\/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget, 8, 44121\u201344130.","journal-title":"Oncotarget"},{"key":"10381_CR224","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.annonc.2023.04.006","volume":"34","author":"C Serrano","year":"2023","unstructured":"Serrano, C., Bauer, S., G\u00f3mez-Peregrina, D., et al. (2023). Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. Annals of Oncology., 34, 615\u2013625.","journal-title":"Annals of Oncology."},{"key":"10381_CR225","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840843","volume":"12","author":"TK Ko","year":"2022","unstructured":"Ko, T. K., Lee, E., Ng, C. C., et al. (2022). Circulating tumor DNA mutations in progressive gastrointestinal stromal tumors identify biomarkers of treatment resistance and uncover potential therapeutic strategies. Frontiers in Oncology, 12, Article 840843.","journal-title":"Frontiers in Oncology"},{"key":"10381_CR226","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1200\/PO.19.00253","volume":"4","author":"J Arshad","year":"2020","unstructured":"Arshad, J., Roberts, A., Ahmed, J., et al. (2020). Utility of circulating tumor DNA in the management of patients with GI stromal tumor: Analysis of 243 patients. JCO Precision Oncology, 4, 66\u201373.","journal-title":"JCO Precision Oncology"},{"key":"10381_CR227","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1080\/14796694.2024.2376521","volume":"20","author":"S George","year":"2024","unstructured":"George, S., Blay, J. Y., Chi, P., et al. (2024). The INSIGHT study: A randomized, phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17\/18 mutations. Future Oncology, 20, 1973\u20131982.","journal-title":"Future Oncology"},{"key":"10381_CR228","doi-asserted-by":"publisher","first-page":"TPS766","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS766","volume":"42","author":"MC Heinrich","year":"2024","unstructured":"Heinrich, M. C., Somaiah, N., Trent, J. C., et al. (2024). Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology, 42, TPS766\u2013TPS766.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR229","doi-asserted-by":"publisher","first-page":"11533","DOI":"10.1200\/JCO.2024.42.16_suppl.11533","volume":"42","author":"AJ Wagner","year":"2024","unstructured":"Wagner, A. J., Trent, J. C., Attia, S., et al. (2024). Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology., 42, 11533\u201311533.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR230","doi-asserted-by":"publisher","first-page":"TPS11579","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS11579","volume":"43","author":"CL Haddox","year":"2025","unstructured":"Haddox, C. L., Ballman, K. V., Mehren, M., et al. (2025). SARC044: A phase II trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy. Journal of Clinical Oncology, 43, TPS11579\u2013TPS11579.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR231","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich, M. C., Jones, R. L., von Mehren, M., et al. (2020). Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): A multicentre, open-label, phase 1 trial. The lancet Oncology, 21, 935\u2013946.","journal-title":"The lancet Oncology"},{"key":"10381_CR232","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","volume":"145","author":"RL Jones","year":"2021","unstructured":"Jones, R. L., Serrano, C., von Mehren, M., et al. (2021). Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer, 145, 132\u2013142.","journal-title":"European Journal of Cancer"},{"key":"10381_CR233","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-20-0487","volume":"11","author":"S Grunewald","year":"2021","unstructured":"Grunewald, S., Klug, L. R., M\u00fchlenberg, T., et al. (2021). Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discovery, 11, 108\u2013125.","journal-title":"Cancer Discovery"},{"key":"10381_CR234","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S1470-2045(13)70453-4","volume":"14","author":"YK Kang","year":"2013","unstructured":"Kang, Y. K., Ryu, M. H., Yoo, C., et al. (2013). Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): A randomised, placebo-controlled, phase 3 trial. Lancet Oncology, 14, 1175\u20131182.","journal-title":"Lancet Oncology"},{"key":"10381_CR235","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/1078-0432.CCR-23-4065","volume":"30","author":"HD Kim","year":"2024","unstructured":"Kim, H. D., Ryu, M. H., Park, Y. S., Yoo, C., Kim, S. J., & Kang, Y. K. (2024). Clinical and biomarker analysis of a phase I\/II study of PDR001 plus imatinib for advanced treatment-refractory gastrointestinal stromal tumors. Clinical Cancer Research, 30, 2743\u20132750.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR236","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George, S., Blay, J. Y., Casali, P. G., et al. (2009). Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. European Journal of Cancer, 45, 1959\u20131968.","journal-title":"European Journal of Cancer"},{"key":"10381_CR237","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-11-3005","volume":"18","author":"GD Demetri","year":"2012","unstructured":"Demetri, G. D., Garrett, C. R., Sch\u00f6ffski, P., et al. (2012). Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clinical Cancer Research, 18, 3170\u20133179.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR238","doi-asserted-by":"publisher","first-page":"S1033","DOI":"10.1016\/j.annonc.2023.09.1149","volume":"34","author":"S Cousin","year":"2023","unstructured":"Cousin, S., Bellera, C., Guegan, J. P., et al. (2023). 1920MO Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort. Annals of Oncology., 34, S1033.","journal-title":"Annals of Oncology."},{"key":"10381_CR239","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1200\/JCO.20.00522","volume":"38","author":"F Janku","year":"2020","unstructured":"Janku, F., Abdul Razak, A. R., Chi, P., et al. (2020). Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: A phase I study of ripretinib. Journal of Clinical Oncology, 38, 3294\u20133303.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR240","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1200\/JCO.21.00217","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang, Y. K., George, S., Jones, R. L., et al. (2021). Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: A randomized, open-label phase III study. Journal of Clinical Oncology, 39, 3128\u20133139.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR241","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.MCT-18-0831","volume":"18","author":"A Shimomura","year":"2019","unstructured":"Shimomura, A., Yamamoto, N., Kondo, S., et al. (2019). First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Molecular Cancer Therapeutics, 18, 531\u2013540.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10381_CR242","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2019.08.009","volume":"121","author":"T Doi","year":"2019","unstructured":"Doi, T., Kurokawa, Y., Sawaki, A., et al. (2019). Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: A phase II, single-arm trial. European Journal of Cancer, 121, 29\u201339.","journal-title":"European Journal of Cancer"},{"key":"10381_CR243","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","volume":"33","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa, Y., Honma, Y., Sawaki, A., et al. (2022). Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): A randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology, 33, 959\u2013967.","journal-title":"Annals of Oncology"},{"key":"10381_CR244","doi-asserted-by":"publisher","first-page":"S1031","DOI":"10.1016\/j.annonc.2023.09.1146","volume":"34","author":"Y Naito","year":"2023","unstructured":"Naito, Y., Komatsu, Y., Kurokawa, Y., Hirano, H., Nishida, T., & Doi, T. (2023). 1917MO CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. Annals of Oncology, 34, S1031\u2013S1032.","journal-title":"Annals of Oncology"},{"key":"10381_CR245","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2016.03.076","volume":"61","author":"AJ Wagner","year":"2016","unstructured":"Wagner, A. J., Agulnik, M., Heinrich, M. C., et al. (2016). Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. European Journal of Cancer, 61, 94\u2013101.","journal-title":"European Journal of Cancer"},{"key":"10381_CR246","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1158\/1078-0432.CCR-13-0953","volume":"19","author":"AJ Wagner","year":"2013","unstructured":"Wagner, A. J., Chugh, R., Rosen, L. S., et al. (2013). A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clinical Cancer Research, 19, 6020\u20136029.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR247","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/annonc\/mds275","volume":"24","author":"MA Dickson","year":"2013","unstructured":"Dickson, M. A., Okuno, S. H., Keohan, M. L., et al. (2013). Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Annals of Oncology, 24, 252\u2013257.","journal-title":"Annals of Oncology"},{"key":"10381_CR248","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/07357907.2016.1193746","volume":"34","author":"JC Bendell","year":"2016","unstructured":"Bendell, J. C., Bauer, T. M., Lamar, R., et al. (2016). A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors. Cancer Investigation, 34, 265\u2013270.","journal-title":"Cancer Investigation"},{"key":"10381_CR249","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/jco.2016.34.4_suppl.134","volume":"34","author":"N-J Chiang","year":"2016","unstructured":"Chiang, N.-J., Yeh, K.-H., Chiu, C.-F., et al. (2016). Results of phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy. Journal of Clinical Oncology., 34, 134\u2013134.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR250","doi-asserted-by":"publisher","first-page":"10011","DOI":"10.1200\/jco.2011.29.15_suppl.10011","volume":"29","author":"GD Demetri","year":"2011","unstructured":"Demetri, G. D., Heinrich, M. C., Chmielowski, B., et al. (2011). An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and\/or unresectable GIST. Journal of Clinical Oncology., 29, 10011\u201310011.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR251","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamaoncol.2021.2086","volume":"7","author":"AJ Wagner","year":"2021","unstructured":"Wagner, A. J., Severson, P. L., Shields, A. F., et al. (2021). Association of combination of conformation-specific KIT inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: A phase 1b\/2a nonrandomized clinical trial. JAMA Oncology, 7, 1343\u20131350.","journal-title":"JAMA Oncology"},{"key":"10381_CR252","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.1200\/JCO.2024.42.16_suppl.11501","volume":"42","author":"P Sch\u00f6ffski","year":"2024","unstructured":"Sch\u00f6ffski, P., Heinrich, M. C., Trent, J. C., et al. (2024). StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs). Journal of Clinical Oncology, 42, 11501\u201311501.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR253","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/annonc\/mdw659","volume":"28","author":"AJ Wagner","year":"2017","unstructured":"Wagner, A. J., Kindler, H., Gelderblom, H., et al. (2017). A phase II study of a human anti-PDGFR\u03b1 monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Annals of Oncology, 28, 541\u2013546.","journal-title":"Annals of Oncology"},{"key":"10381_CR254","doi-asserted-by":"publisher","first-page":"S1032","DOI":"10.1016\/j.annonc.2024.08.1814","volume":"35","author":"H Qiu","year":"2024","unstructured":"Qiu, H., Yang, C., Zhou, Z., et al. (2024). 1722MO Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA). Annals of Oncology., 35, S1032.","journal-title":"Annals of Oncology."},{"key":"10381_CR255","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2020.04.021","volume":"134","author":"P Sch\u00f6ffski","year":"2020","unstructured":"Sch\u00f6ffski, P., Mir, O., Kasper, B., et al. (2020). Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 \u2018CaboGIST.\u2019 European Journal of Cancer, 134, 62\u201374.","journal-title":"European Journal of Cancer"},{"key":"10381_CR256","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri, G. D., Lo Russo, P., MacPherson, I. R., et al. (2009). Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15, 6232\u20136240.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR257","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jamaoncol.2018.0601","volume":"4","author":"SM Schuetze","year":"2018","unstructured":"Schuetze, S. M., Bolejack, V., Thomas, D. G., et al. (2018). Association of dasatinib with progression-free survival among patients with advanced gastrointestinal stromal tumors resistant to imatinib. JAMA Oncology, 4, 814\u2013820.","journal-title":"JAMA Oncology"},{"key":"10381_CR258","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1158\/1078-0432.CCR-16-2349","volume":"23","author":"SP D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo, S. P., Shoushtari, A. N., Keohan, M. L., et al. (2017). Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: A phase Ib study of dasatinib plus ipilimumab. Clinical Cancer Research, 23, 2972\u20132980.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR259","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.31234","volume":"124","author":"M Montemurro","year":"2018","unstructured":"Montemurro, M., Cioffi, A., D\u00f4mont, J., et al. (2018). Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56\/07). Cancer, 124, 1449\u20131454.","journal-title":"Cancer"},{"key":"10381_CR260","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1002\/cam4.3319","volume":"9","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y., Zhang, X., Wu, X., et al. (2020). A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood. Cancer Medicine, 9, 6225\u20136233.","journal-title":"Cancer Medicine"},{"key":"10381_CR261","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/bjc.2017.290","volume":"117","author":"H Joensuu","year":"2017","unstructured":"Joensuu, H., Blay, J. Y., Comandone, A., et al. (2017). Dovitinib in patients with gastrointestinal stromal tumour refractory and\/or intolerant to imatinib. British Journal of Cancer, 117, 1278\u20131285.","journal-title":"British Journal of Cancer"},{"key":"10381_CR262","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/bjc.2013.594","volume":"109","author":"YK Kang","year":"2013","unstructured":"Kang, Y. K., Yoo, C., Ryoo, B. Y., et al. (2013). Phase II study of dovitinib in patients with metastatic and\/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. British Journal of Cancer, 109, 2309\u20132315.","journal-title":"British Journal of Cancer"},{"key":"10381_CR263","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","volume":"46","author":"A Le Cesne","year":"2010","unstructured":"Le Cesne, A., Blay, J. Y., Bui, B. N., et al. (2010). Phase II study of oral masitinib mesilate in imatinib-na\u00efve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer, 46, 1344\u20131351.","journal-title":"European Journal of Cancer"},{"key":"10381_CR264","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1200\/jco.2012.30.15_suppl.10089","volume":"30","author":"AL Cesne","year":"2012","unstructured":"Cesne, A. L., Blay, J.-Y., Nguyen, B. B., et al. (2012). Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial. Journal of Clinical Oncology., 30, 10089\u201310089.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR265","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdu237","volume":"25","author":"A Adenis","year":"2014","unstructured":"Adenis, A., Blay, J. Y., Bui-Nguyen, B., et al. (2014). Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. Annals of Oncology, 25, 1762\u20131769.","journal-title":"Annals of Oncology"},{"key":"10381_CR266","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-09-0542","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri, G. D., Casali, P. G., Blay, J. Y., et al. (2009). A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clinical Cancer Research, 15, 5910\u20135916.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR267","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1002\/cncr.26120","volume":"117","author":"A Sawaki","year":"2011","unstructured":"Sawaki, A., Nishida, T., Doi, T., et al. (2011). Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer, 117, 4633\u20134641.","journal-title":"Cancer"},{"key":"10381_CR268","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00280-011-1785-7","volume":"69","author":"C Cauchi","year":"2012","unstructured":"Cauchi, C., Somaiah, N., Engstrom, P. F., et al. (2012). Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemotherapy and Pharmacology, 69, 977\u2013982.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10381_CR269","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","volume":"23","author":"P Reichardt","year":"2012","unstructured":"Reichardt, P., Blay, J. Y., Gelderblom, H., et al. (2012). Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Annals of Oncology, 23, 1680\u20131687.","journal-title":"Annals of Oncology"},{"key":"10381_CR270","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdt484","volume":"25","author":"KN Ganjoo","year":"2014","unstructured":"Ganjoo, K. N., Villalobos, V. M., Kamaya, A., et al. (2014). A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Annals of Oncology, 25, 236\u2013240.","journal-title":"Annals of Oncology"},{"key":"10381_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100217","volume":"6","author":"M Eriksson","year":"2021","unstructured":"Eriksson, M., Reichardt, P., Joensuu, H., et al. (2021). Benefit of pazopanib in advanced gastrointestinal stromal tumours: Results from a phase II trial (SSG XXI, PAGIST). ESMO Open., 6, Article 100217.","journal-title":"ESMO Open."},{"key":"10381_CR272","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir, O., Cropet, C., Toulmonde, M., et al. (2016). Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): A randomised, multicentre, open-label phase 2 trial. The lancet Oncology, 17, 632\u2013641.","journal-title":"The lancet Oncology"},{"key":"10381_CR273","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/1078-0432.CCR-21-2037","volume":"28","author":"S George","year":"2022","unstructured":"George, S., von Mehren, M., Fletcher, J. A., et al. (2022). Phase II study of ponatinib in advanced gastrointestinal stromal tumors: Efficacy, safety, and impact of liquid biopsy and other biomarkers. Clinical Cancer Research, 28, 1268\u20131276.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR274","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/1078-0432.CCR-25-0222","volume":"31","author":"J Falkenhorst","year":"2025","unstructured":"Falkenhorst, J., Ivanyi, P., Schulz, T., et al. (2025). Phase II trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial). Clinical Cancer Research, 31, 4059\u20134069.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR275","doi-asserted-by":"publisher","first-page":"10009","DOI":"10.1200\/jco.2011.29.15_suppl.10009","volume":"29","author":"HL Kindler","year":"2011","unstructured":"Kindler, H. L., Campbell, N. P., Wroblewski, K., et al. (2011). Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. Journal of Clinical Oncology., 29, 10009\u201310009.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR276","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s10637-012-9795-9","volume":"30","author":"SH Park","year":"2012","unstructured":"Park, S. H., Ryu, M. H., Ryoo, B. Y., et al. (2012). Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: A phase II study of Korean gastrointestinal stromal tumors study group. Investigational New Drugs, 30, 2377\u20132383.","journal-title":"Investigational New Drugs"},{"key":"10381_CR277","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00280-010-1431-9","volume":"68","author":"RS Benjamin","year":"2011","unstructured":"Benjamin, R. S., Sch\u00f6ffski, P., Hartmann, J. T., et al. (2011). Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemotherapy and Pharmacology, 68, 69\u201377.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10381_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115565","volume":"225","author":"PL Rutkowski","year":"2025","unstructured":"Rutkowski, P. L., Klimczak, A., Teterycz, P., et al. (2025). Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor. European Journal of Cancer, 225, Article 115565.","journal-title":"European Journal of Cancer"},{"key":"10381_CR279","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/annonc\/mdm419","volume":"19","author":"H Joensuu","year":"2008","unstructured":"Joensuu, H., De Braud, F., Coco, P., et al. (2008). Phase II, open-label study of PTK787\/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Annals of Oncology, 19, 173\u2013177.","journal-title":"Annals of Oncology"},{"key":"10381_CR280","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/bjc.2011.151","volume":"104","author":"H Joensuu","year":"2011","unstructured":"Joensuu, H., De Braud, F., Grignagni, G., et al. (2011). Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: Final results of a phase II study. British Journal of Cancer, 104, 1686\u20131690.","journal-title":"British Journal of Cancer"},{"key":"10381_CR281","doi-asserted-by":"publisher","first-page":"11518","DOI":"10.1200\/JCO.2024.42.16_suppl.11518","volume":"42","author":"J Li","year":"2024","unstructured":"Li, J., Chi, P., Kang, Y.-K., et al. (2024). Phase 1 study of NB003, a broad-spectrum KIT\/PDGFR\u03b1 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology., 42, 11518\u201311518.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR282","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-13-1881","volume":"20","author":"I Judson","year":"2014","unstructured":"Judson, I., Scurr, M., Gardner, K., et al. (2014). Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clinical Cancer Research, 20, 3603\u20133612.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR283","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1158\/1078-0432.CCR-12-2258","volume":"19","author":"TA Yap","year":"2013","unstructured":"Yap, T. A., Arkenau, H. T., Camidge, D. R., et al. (2013). First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clinical Cancer Research, 19, 909\u2013919.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR284","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1093\/oncolo\/oyac271","volume":"28","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y., Zeng, C., Sun, X., et al. (2023). Activity of anlotinib in the second-line therapy of metastatic gastrointestinal stromal tumors: A prospective, multicenter, in vitro study. The Oncologist, 28, e191\u2013e197.","journal-title":"The Oncologist"},{"key":"10381_CR285","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00280-013-2282-y","volume":"72","author":"A Zhou","year":"2013","unstructured":"Zhou, A., Zhang, W., Chang, C., et al. (2013). Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemotherapy and Pharmacology, 72, 1043\u20131053.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10381_CR286","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1634\/theoncologist.2019-0418","volume":"24","author":"E Rosenbaum","year":"2019","unstructured":"Rosenbaum, E., Kelly, C., D\u2019Angelo, S. P., et al. (2019). A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced gastrointestinal stromal tumor. The Oncologist, 24, 1309-e1983.","journal-title":"The Oncologist"},{"key":"10381_CR287","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-19-0986","volume":"25","author":"J Glod","year":"2019","unstructured":"Glod, J., Arnaldez, F. I., Wiener, L., et al. (2019). A phase II trial of vandetanib in children and adults with succinate dehydrogenase-deficient gastrointestinal stromal tumor. Clinical Cancer Research, 25, 6302\u20136308.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR288","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09610-4","volume":"22","author":"MA Pantaleo","year":"2022","unstructured":"Pantaleo, M. A., Heinrich, M. C., Italiano, A., et al. (2022). A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. BMC Cancer, 22, Article 511.","journal-title":"BMC Cancer"},{"key":"10381_CR289","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41416-020-0769-y","volume":"122","author":"H Gelderblom","year":"2020","unstructured":"Gelderblom, H., Jones, R. L., George, S., et al. (2020). Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: A phase 1b, multicentre study. British Journal of Cancer, 122, 1158\u20131165.","journal-title":"British Journal of Cancer"},{"key":"10381_CR290","doi-asserted-by":"publisher","first-page":"10563","DOI":"10.1200\/jco.2009.27.15_suppl.10563","volume":"27","author":"AP Conley","year":"2009","unstructured":"Conley, A. P., Araujo, D., Ludwig, J., et al. (2009). A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 27, 10563\u201310563.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR291","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/annonc\/mdq076","volume":"21","author":"P Sch\u00f6ffski","year":"2010","unstructured":"Sch\u00f6ffski, P., Reichardt, P., Blay, J. Y., et al. (2010). A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Annals of Oncology, 21, 1990\u20131998.","journal-title":"Annals of Oncology"},{"key":"10381_CR292","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1158\/1078-0432.CCR-21-3909","volume":"28","author":"P Chi","year":"2022","unstructured":"Chi, P., Qin, L. X., Camacho, N., et al. (2022). Phase Ib trial of the combination of imatinib and binimetinib in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research, 28, 1507\u20131517.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR293","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.21.02029","volume":"40","author":"P Chi","year":"2022","unstructured":"Chi, P., Qin, L. X., Nguyen, B., et al. (2022). Phase II trial of imatinib plus binimetinib in patients with treatment-naive advanced gastrointestinal stromal tumor. Journal of Clinical Oncology, 40, 997\u20131008.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR294","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-19-1069","volume":"26","author":"M von Mehren","year":"2020","unstructured":"von Mehren, M., George, S., Heinrich, M. C., et al. (2020). Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study. Clinical Cancer Research, 26, 1837\u20131845.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR295","doi-asserted-by":"publisher","first-page":"S1228","DOI":"10.1016\/j.annonc.2022.07.1592","volume":"33","author":"C Serrano","year":"2022","unstructured":"Serrano, C., Valverde Morales, C. M., Cruz Jurado, J., et al. (2022). 1489MO A phase Ib\/II study of selinexor as single agent and in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST\/GEIS-41 trial. Annals of Oncology., 33, S1228.","journal-title":"Annals of Oncology."},{"key":"10381_CR296","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1158\/1078-0432.CCR-18-3127","volume":"25","author":"M Toulmonde","year":"2019","unstructured":"Toulmonde, M., Blay, J. Y., Bouche, O., et al. (2019). Activity and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A biomarker-driven phase II study. Clinical Cancer Research, 25, 4611\u20134615.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR297","doi-asserted-by":"publisher","first-page":"11512","DOI":"10.1200\/JCO.2022.40.16_suppl.11512","volume":"40","author":"S George","year":"2022","unstructured":"George, S., Heinrich, M. C., Somaiah, N., et al. (2022). A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology., 40, 11512\u201311512.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR298","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102272","author":"OS Santa Gadea","year":"2024","unstructured":"Santa Gadea, O. S., Machiels, J. P., Soo, R. A., et al. (2024). 43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors. ESMO Open. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102272","journal-title":"ESMO Open"},{"key":"10381_CR299","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10637-018-0648-z","volume":"37","author":"CM Kelly","year":"2019","unstructured":"Kelly, C. M., Shoushtari, A. N., Qin, L. X., et al. (2019). A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 37, 282\u2013290.","journal-title":"Investigational New Drugs"},{"key":"10381_CR300","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejca.2006.09.014","volume":"43","author":"M Leahy","year":"2007","unstructured":"Leahy, M., Ray-Coquard, I., Verweij, J., et al. (2007). Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. European Journal of Cancer, 43, 308\u2013315.","journal-title":"European Journal of Cancer"},{"key":"10381_CR301","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","volume":"29","author":"JA Ligon","year":"2023","unstructured":"Ligon, J. A., Sundby, R. T., Wedekind, M. F., et al. (2023). A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma. Clinical Cancer Research, 29, 341\u2013348.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR302","doi-asserted-by":"publisher","first-page":"e15557","DOI":"10.1200\/jco.2013.31.15_suppl.e15557","volume":"31","author":"A Starodub","year":"2013","unstructured":"Starodub, A., Milhem, M. M., Pennington, K. L., et al. (2013). Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib. Journal of Clinical Oncology, 31, e15557.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR303","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-22-3822","volume":"29","author":"L De Sutter","year":"2023","unstructured":"De Sutter, L., Wozniak, A., Verreet, J., et al. (2023). Antitumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST). Clinical Cancer Research, 29, 2859\u20132868.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR304","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1158\/1078-0432.CCR-19-2848","volume":"26","author":"V Pilla Reddy","year":"2020","unstructured":"Pilla Reddy, V., Anjum, R., Grondine, M., et al. (2020). The pharmacokinetic-pharmacodynamic (PKPD) relationships of AZD3229, a novel and selective inhibitor of KIT, in a range of mouse xenograft models of GIST. Clinical Cancer Research, 26, 3751\u20133759.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR305","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1158\/1538-7445.AM2023-4033","volume":"83","author":"BD Smith","year":"2023","unstructured":"Smith, B. D., Vogeti, S., Caldwell, T. M., et al. (2023). Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models. Cancer Research, 83, 4033\u20134033.","journal-title":"Cancer Research"},{"key":"10381_CR306","doi-asserted-by":"publisher","first-page":"TPS11580","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS11580","volume":"43","author":"SR Chandana","year":"2025","unstructured":"Chandana, S. R., George, S., Chi, P., et al. (2025). An open-label phase 1\/2 study of DCC-3009 monotherapy in patients with advanced gastrointestinal stromal tumor. Journal of Clinical Oncology, 43, TPS11580\u2013TPS11580.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR307","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1158\/1538-7445.AM2021-1292","volume":"81","author":"VM Rivera","year":"2021","unstructured":"Rivera, V. M., Huang, W.-S., Lu, M., Pritchard, J. R., Dalgarno, D., & Shakespeare, W. C. (2021). Abstract 1292: Preclinical characterization of THE-630, a next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST). Cancer Research, 81, 1292\u20131292.","journal-title":"Cancer Research"},{"key":"10381_CR308","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2015.04.006","volume":"149","author":"Y Hayashi","year":"2015","unstructured":"Hayashi, Y., Bardsley, M. R., Toyomasu, Y., et al. (2015). Platelet-derived growth factor receptor-\u03b1 regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by stabilizing ETV1. Gastroenterology, 149, 420-432.e416.","journal-title":"Gastroenterology"},{"key":"10381_CR309","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1535-7163.MCT-20-0824","volume":"20","author":"A Gupta","year":"2021","unstructured":"Gupta, A., Singh, J., Garc\u00eda-Valverde, A., Serrano, C., Flynn, D. L., & Smith, B. D. (2021). Ripretinib and MEK inhibitors synergize to induce apoptosis in preclinical models of GIST and systemic mastocytosis. Molecular Cancer Therapeutics, 20, 1234\u20131245.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10381_CR310","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23102643","author":"S Boichuk","year":"2018","unstructured":"Boichuk, S., Galembikova, A., Dunaev, P., et al. (2018). Targeting of FGF-signaling re-sensitizes gastrointestinal stromal tumors (GIST) to imatinib in vitro and in vivo. Molecules. https:\/\/doi.org\/10.3390\/molecules23102643","journal-title":"Molecules"},{"key":"10381_CR311","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1158\/2159-8290.CD-15-0116","volume":"5","author":"A Duensing","year":"2015","unstructured":"Duensing, A. (2015). Targeting ETV1 in gastrointestinal stromal tumors: Tripping the circuit breaker in GIST? Cancer Discovery, 5, 231\u2013233.","journal-title":"Cancer Discovery"},{"key":"10381_CR312","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1245\/s10434-023-13519-y","volume":"30","author":"HV Kwak","year":"2023","unstructured":"Kwak, H. V., Tardy, K. J., Allbee, A., Stashek, K., & DeMatteo, R. P. (2023). Surgical management of germline gastrointestinal stromal tumor. Annals of Surgical Oncology, 30, 4966\u20134974.","journal-title":"Annals of Surgical Oncology"},{"key":"10381_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104477","volume":"10","author":"C Cuvelier","year":"2025","unstructured":"Cuvelier, C., Brahmi, M., Sobhani, I., et al. (2025). Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: A retrospective study from the NETSARC. ESMO Open., 10, Article 104477.","journal-title":"ESMO Open."},{"key":"10381_CR314","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E., Baldwin, A., Marcus, L. J., et al. (2016). Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. New England Journal of Medicine, 375, 2550\u20132560.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR315","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M., Wolters, P. L., Dombi, E., et al. (2020). Selumetinib in children with inoperable plexiform neurofibromas. New England Journal of Medicine, 382, 1430\u20131442.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR316","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00421","volume":"7","author":"KB Wisinski","year":"2023","unstructured":"Wisinski, K. B., Flamand, Y., Wilson, M. A., et al. (2023). Trametinib in patients with NF1-, GNAQ-, or GNA11-mutant tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols S1 and S2. JCO Precision Oncology, 7, Article e2200421.","journal-title":"JCO Precision Oncology"},{"key":"10381_CR317","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00649","volume":"8","author":"M Fukuda","year":"2024","unstructured":"Fukuda, M., Mukohara, T., Kuwata, T., Sunami, K., & Naito, Y. (2024). Efficacy of trametinib in neurofibromatosis type 1-associated gastrointestinal stromal tumors: A case report. JCO Precision Oncology, 8, Article e2300649.","journal-title":"JCO Precision Oncology"},{"key":"10381_CR318","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/modpathol.2014.53","volume":"27","author":"A Quattrone","year":"2014","unstructured":"Quattrone, A., Wozniak, A., Dewaele, B., et al. (2014). Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Modern Pathology, 27, 1510\u20131520.","journal-title":"Modern Pathology"},{"key":"10381_CR319","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/1078-0432.CCR-12-2853","volume":"19","author":"G Floris","year":"2013","unstructured":"Floris, G., Wozniak, A., Sciot, R., et al. (2013). A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: Long-lasting responses after treatment withdrawal. Clinical Cancer Research, 19, 620\u2013630.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR320","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-14-1823","volume":"20","author":"T Van Looy","year":"2014","unstructured":"Van Looy, T., Wozniak, A., Floris, G., et al. (2014). Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: Rationale and efficacy. Clinical Cancer Research, 20, 6071\u20136082.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR321","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00105","volume":"6","author":"S Cohen-Gogo","year":"2022","unstructured":"Cohen-Gogo, S., Kanwar, N., Shaikh, F., et al. (2022). Response to alpelisib in an adolescent with PIK3CA-mutated metastatic gastrointestinal stromal tumor. JCO Precision Oncology, 6, Article e2200105.","journal-title":"JCO Precision Oncology"},{"key":"10381_CR322","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","volume":"27","author":"E Ben-Ami","year":"2016","unstructured":"Ben-Ami, E., Barysauskas, C. M., von Mehren, M., et al. (2016). Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Annals of Oncology, 27, 1794\u20131799.","journal-title":"Annals of Oncology"},{"key":"10381_CR323","doi-asserted-by":"publisher","first-page":"11540","DOI":"10.1200\/JCO.2023.41.16_suppl.11540","volume":"41","author":"H Qiu","year":"2023","unstructured":"Qiu, H., Zhou, Z.-w, Zhou, Y., et al. (2023). Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)\u2013resistant succinate dehydrogenase (SDH)\u2013deficient gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 41, 11540\u201311540.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR324","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/s41591-026-04376-9","volume":"32","author":"P Merriam","year":"2026","unstructured":"Merriam, P., Morrow, J. J., Mazzola, E., et al. (2026). Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: A phase 2 trial. Nature Medicine, 32, 2191\u20132200.","journal-title":"Nature Medicine"},{"key":"10381_CR325","doi-asserted-by":"publisher","first-page":"9941","DOI":"10.2147\/CMAR.S269388","volume":"12","author":"L Lou","year":"2020","unstructured":"Lou, L., Zhang, W., Li, J., & Wang, Y. (2020). Abnormal MGMT promoter methylation in gastrointestinal stromal tumors: Genetic susceptibility and association with clinical outcome. Cancer Manag Res., 12, 9941\u20139952.","journal-title":"Cancer Manag Res."},{"key":"10381_CR326","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-21-2092","volume":"28","author":"M Yebra","year":"2022","unstructured":"Yebra, M., Bhargava, S., Kumar, A., et al. (2022). Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor models for predicting therapeutic response. Clinical Cancer Research, 28, 187\u2013200.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR327","doi-asserted-by":"publisher","first-page":"8784","DOI":"10.1038\/ncomms9784","volume":"6","author":"C Lussey-Lepoutre","year":"2015","unstructured":"Lussey-Lepoutre, C., Hollinshead, K. E., Ludwig, C., et al. (2015). Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nature Communications, 6, 8784.","journal-title":"Nature Communications"},{"key":"10381_CR328","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/ncb3233","volume":"17","author":"S Cardaci","year":"2015","unstructured":"Cardaci, S., Zheng, L., MacKay, G., et al. (2015). Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nature Cell Biology, 17, 1317\u20131326.","journal-title":"Nature Cell Biology"},{"key":"10381_CR329","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030599","author":"B Sarkadi","year":"2020","unstructured":"Sarkadi, B., Meszaros, K., Krencz, I., et al. (2020). Glutaminases as a novel target for SDHB-associated pheochromocytomas\/paragangliomas. Cancers. https:\/\/doi.org\/10.3390\/cancers12030599","journal-title":"Cancers"},{"key":"10381_CR330","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","volume":"27","author":"JJ Harding","year":"2021","unstructured":"Harding, J. J., Telli, M., Munster, P., et al. (2021). A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors. Clinical Cancer Research, 27, 4994\u20135003.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR331","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/PAS.0000000000000418","volume":"39","author":"S Rossi","year":"2015","unstructured":"Rossi, S., Gasparotto, D., Miceli, R., et al. (2015). KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: A population-based study. American Journal of Surgical Pathology, 39, 922\u2013930.","journal-title":"American Journal of Surgical Pathology"},{"key":"10381_CR332","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091707","author":"RA Denu","year":"2024","unstructured":"Denu, R. A., Joseph, C. P., Urquiola, E. S., et al. (2024). Utility of clinical next generation sequencing tests in KIT\/PDGFRA\/SDH wild-type gastrointestinal stromal tumors. Cancers. https:\/\/doi.org\/10.3390\/cancers16091707","journal-title":"Cancers"},{"key":"10381_CR333","doi-asserted-by":"crossref","unstructured":"Gouda, M. A., Subbiah, V.\u00a0(2023). Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E&#x2013;positive adult and pediatric solid tumors. American Society of Clinical Oncology Educational Book e404770.","DOI":"10.1200\/EDBK_404770"},{"key":"10381_CR334","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V., Kreitman, R. J., Wainberg, Z. A., et al. (2023). Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial. Nature Medicine, 29, 1103\u20131112.","journal-title":"Nature Medicine"},{"key":"10381_CR335","doi-asserted-by":"publisher","first-page":"788","DOI":"10.21037\/jgo-23-767","volume":"15","author":"S Gowda","year":"2024","unstructured":"Gowda, S., Sandow, L., & Heinrich, M. C. (2024). Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: A case report. J Gastrointest Oncol., 15, 788\u2013793.","journal-title":"J Gastrointest Oncol."},{"key":"10381_CR336","doi-asserted-by":"publisher","first-page":"310","DOI":"10.18632\/oncotarget.864","volume":"4","author":"GS Falchook","year":"2013","unstructured":"Falchook, G. S., Trent, J. C., Heinrich, M. C., et al. (2013). BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget, 4, 310\u2013315.","journal-title":"Oncotarget"},{"key":"10381_CR337","doi-asserted-by":"publisher","first-page":"238","DOI":"10.6004\/jnccn.2017.7039","volume":"16","author":"LM Charo","year":"2018","unstructured":"Charo, L. M., Burgoyne, A. M., Fanta, P. T., et al. (2018). A novel PRKAR1B-BRAF fusion in gastrointestinal stromal tumor guides adjuvant treatment decision-making during pregnancy. Journal of the National Comprehensive Cancer Network, 16, 238\u2013242.","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10381_CR338","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/gcc.22991","volume":"60","author":"D Torrence","year":"2021","unstructured":"Torrence, D., Xie, Z., Zhang, L., Chi, P., & Antonescu, C. R. (2021). Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls. Genes, Chromosomes & Cancer, 60, 789\u2013795.","journal-title":"Genes, Chromosomes & Cancer"},{"key":"10381_CR339","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-08-0651","volume":"15","author":"CJ Thiele","year":"2009","unstructured":"Thiele, C. J., Li, Z., & McKee, A. E. (2009). On Trk\u2013the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clinical Cancer Research, 15, 5962\u20135967.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR340","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12029-020-00423-x","volume":"52","author":"R D\u2019Alpino Peixoto","year":"2021","unstructured":"D\u2019Alpino Peixoto, R., Medeiros, B. A., & Cronemberger, E. H. (2021). Resected high-risk rectal GIST harboring NTRK1 fusion: A case report and review of the literature. Journal of Gastrointestinal Cancer, 52, 316\u2013319.","journal-title":"Journal of Gastrointestinal Cancer"},{"key":"10381_CR341","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010105","author":"Z Cao","year":"2022","unstructured":"Cao, Z., Li, J., Sun, L., et al. (2022). GISTs with NTRK gene fusions: A clinicopathological, immunophenotypic, and molecular study. Cancers. https:\/\/doi.org\/10.3390\/cancers15010105","journal-title":"Cancers"},{"key":"10381_CR342","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073707","author":"I Machado","year":"2024","unstructured":"Machado, I., Claramunt-Alonso, R., Lavernia, J., et al. (2024). ETV6: : NTRK3 fusion-positive wild-type gastrointestinal stromal tumor (GIST) with abundant lymphoid infiltration (TILs and tertiary lymphoid structures): A report on a new case with therapeutic implications and a literature review. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms25073707","journal-title":"International Journal of Molecular Sciences"},{"key":"10381_CR343","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-24-3203","volume":"31","author":"T Ranjbarian","year":"2025","unstructured":"Ranjbarian, T., Antkowiak, M., Mallory, R. J., et al. (2025). A systematic review with a demonstrative case of KIT and DOG-1 expressing gastrointestinal stromal tumors harboring ETV6-NTRK3 fusions. Clinical Cancer Research, 31, 2056\u20132061.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR344","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A., Laetsch, T. W., Kummar, S., et al. (2018). Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. New England Journal of Medicine, 378, 731\u2013739.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR345","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong, D. S., DuBois, S. G., Kummar, S., et al. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials. The lancet Oncology, 21, 531\u2013540.","journal-title":"The lancet Oncology"},{"key":"10381_CR346","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/cncr.35036","volume":"129","author":"S Kummar","year":"2023","unstructured":"Kummar, S., Shen, L., Hong, D. S., et al. (2023). Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer, 129, 3772\u20133782.","journal-title":"Cancer"},{"key":"10381_CR347","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41379-020-0623-z","volume":"34","author":"MA Atiq","year":"2021","unstructured":"Atiq, M. A., Davis, J. L., Hornick, J. L., et al. (2021). Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: A clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Modern Pathology, 34, 95\u2013103.","journal-title":"Modern Pathology"},{"key":"10381_CR348","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41379-020-00657-x","volume":"34","author":"I Br\u010di\u0107","year":"2021","unstructured":"Br\u010di\u0107, I., Godschachner, T. M., Bergovec, M., et al. (2021). Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Modern Pathology, 34, 396\u2013407.","journal-title":"Modern Pathology"},{"key":"10381_CR349","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","volume":"31","author":"GD Demetri","year":"2020","unstructured":"Demetri, G. D., Antonescu, C. R., Bjerkehagen, B., et al. (2020). Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: Expert recommendations from the World Sarcoma Network. Annals of Oncology, 31, 1506\u20131517.","journal-title":"Annals of Oncology"},{"key":"10381_CR350","doi-asserted-by":"publisher","first-page":"19829","DOI":"10.1038\/s41598-020-76519-y","volume":"10","author":"M Urbini","year":"2020","unstructured":"Urbini, M., Astolfi, A., Indio, V., et al. (2020). Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT\/PDGFRA\/SDH\/RAS-P WT GIST. Science and Reports, 10, 19829.","journal-title":"Science and Reports"},{"key":"10381_CR351","doi-asserted-by":"publisher","first-page":"S1265","DOI":"10.1016\/j.annonc.2024.08.2322","volume":"35","author":"A Le Cesne","year":"2024","unstructured":"Le Cesne, A., Cropet, C., Brahmi, M., et al. (2024). LBA79 LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib. Annals of Oncology., 35, S1265\u2013S1266.","journal-title":"Annals of Oncology."},{"key":"10381_CR352","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","volume":"40","author":"L Chen","year":"2021","unstructured":"Chen, L., Zhang, Y., Yin, L., et al. (2021). Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges. Journal of Experimental & Clinical Cancer Research, 40, 345.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10381_CR353","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z. A., & Katoh, M. (2024). FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions. Nature Reviews. Clinical Oncology, 21, 312\u2013329.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10381_CR354","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y., Matsubara, N., Park, S. H., et al. (2023). Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. New England Journal of Medicine, 389, 1961\u20131971.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR355","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L., Meric-Bernstam, F., Hollebecque, A., et al. (2023). Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. New England Journal of Medicine, 388, 228\u2013239.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR356","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00504","volume":"10","author":"A Astolfi","year":"2020","unstructured":"Astolfi, A., Indio, V., Nannini, M., et al. (2020). Targeted deep sequencing uncovers cryptic KIT mutations in KIT\/PDGFRA\/SDH\/RAS-P wild-type GIST. Frontiers in Oncology, 10, Article 504.","journal-title":"Frontiers in Oncology"},{"key":"10381_CR357","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell, L., & Lindquist, S. L. (2005). HSP90 and the chaperoning of cancer. Nature Reviews Cancer, 5, 761\u2013772.","journal-title":"Nature Reviews Cancer"},{"key":"10381_CR358","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1158\/0008-5472.CAN-05-0933","volume":"65","author":"T Shimamura","year":"2005","unstructured":"Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005). Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Research, 65, 6401\u20136408.","journal-title":"Cancer Research"},{"key":"10381_CR359","doi-asserted-by":"publisher","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","volume":"66","author":"S Bauer","year":"2006","unstructured":"Bauer, S., Yu, L. K., Demetri, G. D., & Fletcher, J. A. (2006). Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Research, 66, 9153\u20139161.","journal-title":"Cancer Research"},{"key":"10381_CR360","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-21-1929","volume":"27","author":"A Kawazoe","year":"2021","unstructured":"Kawazoe, A., Itahashi, K., Yamamoto, N., et al. (2021). TAS-116 (pimitespib), an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704). Clinical Cancer Research, 27, 6709\u20136715.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR361","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2011","unstructured":"Balachandran, V. P., Cavnar, M. J., Zeng, S., et al. (2011). Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine, 17, 1094\u20131100.","journal-title":"Nature Medicine"},{"key":"10381_CR362","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ijc.25113","volume":"127","author":"M van Dongen","year":"2010","unstructured":"van Dongen, M., Savage, N. D., Jordanova, E. S., et al. (2010). Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. International Journal of Cancer, 127, 899\u2013909.","journal-title":"International Journal of Cancer"},{"key":"10381_CR363","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","volume":"73","author":"S Rusakiewicz","year":"2013","unstructured":"Rusakiewicz, S., Semeraro, M., Sarabi, M., et al. (2013). Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Research, 73, 3499\u20133510.","journal-title":"Cancer Research"},{"key":"10381_CR364","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde, M., Penel, N., Adam, J., et al. (2018). Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial. JAMA Oncology, 4, 93\u201397.","journal-title":"JAMA Oncology"},{"key":"10381_CR365","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1617588","volume":"8","author":"MA Pantaleo","year":"2019","unstructured":"Pantaleo, M. A., Tarantino, G., Agostinelli, C., et al. (2019). Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. Oncoimmunology., 8, Article e1617588.","journal-title":"Oncoimmunology."},{"key":"10381_CR366","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/his.13382","volume":"72","author":"AM Blakely","year":"2018","unstructured":"Blakely, A. M., Matoso, A., Patil, P. A., et al. (2018). Role of immune microenvironment in gastrointestinal stromal tumours. Histopathology, 72, 405\u2013413.","journal-title":"Histopathology"},{"key":"10381_CR367","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789915","volume":"11","author":"X Sun","year":"2021","unstructured":"Sun, X., Shu, P., Fang, Y., et al. (2021). Clinical and prognostic significance of tumor-infiltrating CD8+ T cells and PD-L1 expression in primary gastrointestinal stromal tumors. Frontiers in Oncology, 11, Article 789915.","journal-title":"Frontiers in Oncology"},{"key":"10381_CR368","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s11605-020-04860-8","volume":"25","author":"X Sun","year":"2021","unstructured":"Sun, X., Sun, J., Yuan, W., et al. (2021). Immune cell infiltration and the expression of PD-1 and PD-L1 in primary PDGFRA-mutant gastrointestinal stromal tumors. Journal of Gastrointestinal Surgery, 25, 2091\u20132100.","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10381_CR369","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41419-024-06571-3","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu, X., Yu, J., Li, Y., et al. (2024). Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution. Cell Death & Disease, 15, 190.","journal-title":"Cell Death & Disease"},{"key":"10381_CR370","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nm.2366","volume":"17","author":"NF Delahaye","year":"2011","unstructured":"Delahaye, N. F., Rusakiewicz, S., Martins, I., et al. (2011). Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nature Medicine, 17, 700\u2013707.","journal-title":"Nature Medicine"},{"key":"10381_CR371","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3892\/or.2015.4149","volume":"34","author":"H Komita","year":"2015","unstructured":"Komita, H., Koido, S., Hayashi, K., et al. (2015). Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3\/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. Oncology Reports, 34, 2099\u20132105.","journal-title":"Oncology Reports"},{"key":"10381_CR372","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/cas.14795","volume":"112","author":"X Mao","year":"2021","unstructured":"Mao, X., Yang, X., Chen, X., et al. (2021). Single-cell transcriptome analysis revealed the heterogeneity and microenvironment of gastrointestinal stromal tumors. Cancer Science, 112, 1262\u20131274.","journal-title":"Cancer Science"},{"key":"10381_CR373","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142560","author":"D Gasparotto","year":"2020","unstructured":"Gasparotto, D., Sbaraglia, M., Rossi, S., et al. (2020). Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.142560","journal-title":"JCI Insight"},{"key":"10381_CR374","doi-asserted-by":"publisher","first-page":"1792036","DOI":"10.1080\/2162402X.2020.1792036","volume":"9","author":"A Dufresne","year":"2020","unstructured":"Dufresne, A., Lesluyes, T., M\u00e9n\u00e9trier-Caux, C., et al. (2020). Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. Oncoimmunology., 9, 1792036.","journal-title":"Oncoimmunology."},{"key":"10381_CR375","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/cgt.2016.58","volume":"24","author":"Y Tan","year":"2017","unstructured":"Tan, Y., Trent, J. C., Wilky, B. A., Kerr, D. A., & Rosenberg, A. E. (2017). Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Therapy, 24, 130\u2013133.","journal-title":"Cancer Gene Therapy"},{"key":"10381_CR376","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","volume":"46","author":"SP D\u2019Angelo","year":"2015","unstructured":"D\u2019Angelo, S. P., Shoushtari, A. N., Agaram, N. P., et al. (2015). Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 46, 357\u2013365.","journal-title":"Human Pathology"},{"key":"10381_CR377","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","volume":"23","author":"AM Seifert","year":"2017","unstructured":"Seifert, A. M., Zeng, S., Zhang, J. Q., et al. (2017). PD-1\/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors. Clinical Cancer Research, 23, 454\u2013465.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR378","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1002729","volume":"4","author":"F Bertucci","year":"2015","unstructured":"Bertucci, F., Finetti, P., Mamessier, E., et al. (2015). PDL1 expression is an independent prognostic factor in localized GIST. OncoImmunology, 4, Article e1002729.","journal-title":"OncoImmunology"},{"key":"10381_CR379","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano, C., & George, S. (2020). Gastrointestinal stromal tumor: Challenges and opportunities for a new decade. Clinical Cancer Research, 26, 5078\u20135085.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR380","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-21-0878","volume":"28","author":"AS Singh","year":"2022","unstructured":"Singh, A. S., Hecht, J. R., Rosen, L., et al. (2022). A randomized phase II study of nivolumab monotherapy or nivolumab combined with ipilimumab in patients with advanced gastrointestinal stromal tumors. Clinical Cancer Research, 28, 84\u201394.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR381","doi-asserted-by":"publisher","first-page":"11511","DOI":"10.1200\/JCO.2020.38.15_suppl.11511","volume":"38","author":"JL Chen","year":"2020","unstructured":"Chen, J. L., Mahoney, M. R., George, S., et al. (2020). A multicenter phase II study of nivolumab +\/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts. Journal of Clinical Oncology, 38, 11511\u201311511.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR382","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009472","author":"ND Seligson","year":"2024","unstructured":"Seligson, N. D., Chen, J. L., Goodrich, A. C., et al. (2024). A multicenter, randomized, non-comparative, phase II study of nivolumab \u00b1 ipilimumab for patients with metastatic sarcoma (Alliance A091401): Expansion cohorts and correlative analyses. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-009472","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10381_CR383","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-017-0238-1","volume":"5","author":"MJ Reilley","year":"2017","unstructured":"Reilley, M. J., Bailey, A., Subbiah, V., et al. (2017). Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Journal for Immunotherapy of Cancer, 5, 35.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10381_CR384","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00262-011-1185-1","volume":"61","author":"LL Chen","year":"2012","unstructured":"Chen, L. L., Chen, X., Choi, H., et al. (2012). Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunology, Immunotherapy, 61, 1113\u20131124.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10381_CR385","doi-asserted-by":"publisher","first-page":"S1032","DOI":"10.1016\/j.annonc.2024.08.1815","volume":"35","author":"P Rutkowski","year":"2024","unstructured":"Rutkowski, P., Klimczak, A., Teterycz, P., et al. (2024). 1723MO Axitinib plus avelumab in patients with unresectable\/metastatic gastrointestinal stromal tumor (GIST) after failure of standard therapy: Single-arm phase II study (AXAGIST). Annals of Oncology., 35, S1032.","journal-title":"Annals of Oncology."},{"key":"10381_CR386","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00262-020-02625-5","volume":"69","author":"R Fr\u00f6bom","year":"2020","unstructured":"Fr\u00f6bom, R., Berglund, E., Berglund, D., et al. (2020). Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors. Cancer Immunology, Immunotherapy, 69, 2393\u20132401.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10381_CR387","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F., de Reyni\u00e8s, A., Keung, E. Z., et al. (2020). B cells are associated with survival and immunotherapy response in sarcoma. Nature, 577, 556\u2013560.","journal-title":"Nature"},{"key":"10381_CR388","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M., Lunceford, J., Nebozhyn, M., et al. (2017). IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. The Journal of Clinical Investigation, 127, 2930\u20132940.","journal-title":"The Journal of Clinical Investigation"},{"key":"10381_CR389","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","volume":"6","author":"P Danaher","year":"2018","unstructured":"Danaher, P., Warren, S., Lu, R., et al. (2018). Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA). Journal for Immunotherapy of Cancer, 6, 63.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10381_CR390","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI124108","volume":"129","author":"GA Vitiello","year":"2019","unstructured":"Vitiello, G. A., Bowler, T. G., Liu, M., et al. (2019). Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. The Journal of Clinical Investigation, 129, 1863\u20131877.","journal-title":"The Journal of Clinical Investigation"},{"key":"10381_CR391","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fimmu.2020.00851","volume":"11","author":"V Indio","year":"2020","unstructured":"Indio, V., Ravegnini, G., Astolfi, A., et al. (2020). Gene expression profiling of PDGFRA mutant GIST reveals immune signatures as a specific fingerprint of D842V exon 18 mutation. Frontiers in Immunology, 11, 851.","journal-title":"Frontiers in Immunology"},{"key":"10381_CR392","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104642","volume":"384","author":"H Cai","year":"2023","unstructured":"Cai, H., Chen, Y., Chen, X., Sun, W., & Li, Y. (2023). Tumor-associated macrophages mediate gastrointestinal stromal tumor cell metastasis through CXCL2\/CXCR2. Cellular Immunology, 384, Article 104642.","journal-title":"Cellular Immunology"},{"key":"10381_CR393","doi-asserted-by":"publisher","first-page":"1710064","DOI":"10.1080\/2162402X.2019.1710064","volume":"9","author":"BA Schroeder","year":"2020","unstructured":"Schroeder, B. A., Kohli, K., O\u2019Malley, R. B., et al. (2020). Durable tumor regression in highly refractory metastatic KIT\/PDGFRA wild-type GIST following treatment with nivolumab. Oncoimmunology., 9, 1710064.","journal-title":"Oncoimmunology."},{"key":"10381_CR394","doi-asserted-by":"publisher","first-page":"11053","DOI":"10.1200\/JCO.2017.35.15_suppl.11053","volume":"35","author":"M Toulmonde","year":"2017","unstructured":"Toulmonde, M., Penel, N., Adam, J., et al. (2017). Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial. Journal of Clinical Oncology., 35, 11053\u201311053.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR395","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20833","volume":"3","author":"EV Schmidt","year":"2020","unstructured":"Schmidt, E. V., Chisamore, M. J., Chaney, M. F., et al. (2020). Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials. JAMA Network Open, 3, Article e1920833.","journal-title":"JAMA Network Open"},{"key":"10381_CR396","doi-asserted-by":"publisher","first-page":"11","DOI":"10.23922\/jarc.2020-064","volume":"5","author":"A Ooki","year":"2021","unstructured":"Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021). Immunotherapy in colorectal cancer: Current and future strategies. J Anus Rectum Colon., 5, 11\u201324.","journal-title":"J Anus Rectum Colon."},{"key":"10381_CR397","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40425-017-0255-0","volume":"5","author":"A Laurell","year":"2017","unstructured":"Laurell, A., L\u00f6nnemark, M., Brekkan, E., et al. (2017). Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: A first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. Journal for Immunotherapy of Cancer, 5, 52.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10381_CR398","doi-asserted-by":"crossref","unstructured":"Kim, C., Park, J., Kim, J.O., et al. (2025). Preclinical antitumor efficacy of a novel anti-c-Kit antibody-drug conjugate, NN3201, in c-Kit-positive tumors. Mol Cancer Ther Of1-of14.","DOI":"10.1158\/1535-7163.30986129"},{"key":"10381_CR399","first-page":"8624","volume":"61","author":"SV Allander","year":"2001","unstructured":"Allander, S. V., Nupponen, N. N., Ringn\u00e9r, M., et al. (2001). Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Research, 61, 8624\u20138628.","journal-title":"Cancer Research"},{"key":"10381_CR400","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-03-0715","volume":"10","author":"CR Antonescu","year":"2004","unstructured":"Antonescu, C. R., Viale, A., Sarran, L., et al. (2004). Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clinical Cancer Research, 10, 3282\u20133290.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR401","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1158\/2159-8290.CD-20-1434","volume":"11","author":"K Iida","year":"2021","unstructured":"Iida, K., Abdelhamid Ahmed, A. H., Nagatsuma, A. K., et al. (2021). Identification and therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumors, with DS-6157a, a first-in-class antibody-drug conjugate. Cancer Discovery, 11, 1508\u20131523.","journal-title":"Cancer Discovery"},{"key":"10381_CR402","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg, J., El-Haddad, G., Wolin, E., et al. (2017). Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine, 376, 125\u2013135.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR403","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O., de Bono, J., Chi, K. N., et al. (2021). Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. New England Journal of Medicine, 385, 1091\u20131103.","journal-title":"New England Journal of Medicine"},{"key":"10381_CR404","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00259-004-1476-2","volume":"31","author":"JC Reubi","year":"2004","unstructured":"Reubi, J. C., K\u00f6rner, M., Waser, B., Mazzucchelli, L., & Guillou, L. (2004). High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 31, 803\u2013810.","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10381_CR405","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1089\/cbr.2016.2092","volume":"31","author":"A Paulmichl","year":"2016","unstructured":"Paulmichl, A., Summer, D., Manzl, C., et al. (2016). Targeting gastrointestinal stromal tumor with (68)Ga-labeled peptides: An in vitro study on gastrointestinal stromal tumor-cell lines. Cancer Biotherapy & Radiopharmaceuticals, 31, 302\u2013310.","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"key":"10381_CR406","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100105","author":"M Berndsen","year":"2024","unstructured":"Berndsen, M., Puls, F., Thornell, A., et al. (2024). Gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours. ESMO Gastrointestinal Oncology. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100105","journal-title":"ESMO Gastrointestinal Oncology"},{"key":"10381_CR407","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","volume":"61","author":"L Gruber","year":"2020","unstructured":"Gruber, L., Jim\u00e9nez-Franco, L. D., Decristoforo, C., et al. (2020). MITIGATE-NeoBOMB1, a phase I\/IIa study to evaluate safety, pharmacokinetics, and preliminary imaging of (68)Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients. Journal of Nuclear Medicine, 61, 1749\u20131755.","journal-title":"Journal of Nuclear Medicine"},{"key":"10381_CR408","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051051","author":"C Montemagno","year":"2021","unstructured":"Montemagno, C., Raes, F., Ahmadi, M., et al. (2021). In vivo biodistribution and efficacy evaluation of NeoB, a radiotracer targeted to GRPR, in mice bearing gastrointestinal stromal tumor. Cancers. https:\/\/doi.org\/10.3390\/cancers13051051","journal-title":"Cancers"},{"key":"10381_CR409","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1158\/2159-8290.CD-21-0646","volume":"12","author":"ML Hemming","year":"2022","unstructured":"Hemming, M. L., Benson, M. R., Loycano, M. A., et al. (2022). MOZ and Menin-MLL complexes are complementary regulators of chromatin association and transcriptional output in gastrointestinal stromal tumor. Cancer Discovery, 12, 1804\u20131823.","journal-title":"Cancer Discovery"},{"key":"10381_CR410","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS11578","volume":"43","author":"MM Gounder","year":"2025","unstructured":"Gounder, M. M., Patel, S., Sicklick, J. K., et al. (2025). Phase 1a\/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure. Journal of Clinical Oncology, 43, Article TPS11578-TPS11578.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR411","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister, S. X., Markkanen, E., Jiang, Y., et al. (2015). Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell, 28, 557\u2013568.","journal-title":"Cancer Cell"},{"key":"10381_CR412","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1158\/2767-9764.CRC-24-0213","volume":"4","author":"E Maldonado","year":"2024","unstructured":"Maldonado, E., Rathmell, W. K., Shapiro, G. I., et al. (2024). A phase II trial of the WEE1 inhibitor adavosertib in SETD2-altered advanced solid tumor malignancies (NCI 10170). Cancer Res Commun., 4, 1793\u20131801.","journal-title":"Cancer Res Commun."},{"key":"10381_CR413","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder, M., Sch\u00f6ffski, P., Jones, R. L., et al. (2020). Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: An international, open-label, phase 2 basket study. The lancet Oncology, 21, 1423\u20131432.","journal-title":"The lancet Oncology"},{"key":"10381_CR414","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","volume":"25","author":"PL Zinzani","year":"2024","unstructured":"Zinzani, P. L., Izutsu, K., Mehta-Shah, N., et al. (2024). Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study. The lancet Oncology, 25, 1602\u20131613.","journal-title":"The lancet Oncology"},{"key":"10381_CR415","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","volume":"23","author":"MG Zauderer","year":"2022","unstructured":"Zauderer, M. G., Szlosarek, P. W., Le Moulec, S., et al. (2022). EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study. The lancet Oncology, 23, 758\u2013767.","journal-title":"The lancet Oncology"},{"key":"10381_CR416","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41374-019-0322-x","volume":"100","author":"P Li","year":"2020","unstructured":"Li, P., Li, M., Wang, K., et al. (2020). Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors. Laboratory Investigation, 100, 426\u2013437.","journal-title":"Laboratory Investigation"},{"key":"10381_CR417","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12253-019-00770-6","volume":"26","author":"J Du","year":"2020","unstructured":"Du, J., Wang, S., Wang, R., et al. (2020). Identifying secondary mutations in Chinese patients with imatinib-resistant gastrointestinal stromal tumors (GISTs) by next generation sequencing (NGS). Pathology & Oncology Research, 26, 91\u2013100.","journal-title":"Pathology & Oncology Research"},{"key":"10381_CR418","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler, B. G., Aird, K. M., Garipov, A., et al. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 21, 231\u2013238.","journal-title":"Nature Medicine"},{"key":"10381_CR419","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-24-0398","volume":"84","author":"PJ Keller","year":"2024","unstructured":"Keller, P. J., Adams, E. J., Wu, R., et al. (2024). Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers. Cancer Research, 84, 2501\u20132517.","journal-title":"Cancer Research"},{"key":"10381_CR420","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/1878-0261.12332","volume":"12","author":"E Serrano-Candelas","year":"2018","unstructured":"Serrano-Candelas, E., Ainsua-Enrich, E., Navin\u00e9s-Ferrer, A., et al. (2018). Silencing of adaptor protein SH3BP2 reduces KIT\/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth. Molecular Oncology, 12, 1383\u20131397.","journal-title":"Molecular Oncology"},{"key":"10381_CR421","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41417-022-00539-1","volume":"30","author":"E Proa\u00f1o-P\u00e9rez","year":"2023","unstructured":"Proa\u00f1o-P\u00e9rez, E., Serrano-Candelas, E., Garc\u00eda-Valverde, A., et al. (2023). The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth. Cancer Gene Therapy, 30, 245\u2013255.","journal-title":"Cancer Gene Therapy"},{"key":"10381_CR422","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200983","volume":"33","author":"M Guerrero","year":"2025","unstructured":"Guerrero, M., Proa\u00f1o-P\u00e9rez, E., Serrano-Candelas, E., et al. (2025). Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth. Mol Ther Oncol., 33, Article 200983.","journal-title":"Mol Ther Oncol."},{"key":"10381_CR423","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1158\/0008-5472.CAN-20-3580","volume":"81","author":"X Lu","year":"2021","unstructured":"Lu, X., Pang, Y., Cao, H., et al. (2021). Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Research, 81, 2481\u20132494.","journal-title":"Cancer Research"},{"key":"10381_CR424","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2045-3329-4-9","volume":"4","author":"MA Pantaleo","year":"2014","unstructured":"Pantaleo, M. A., Astolfi, A., Urbini, M., et al. (2014). Dystrophin deregulation is associated with tumor progression in KIT\/PDGFRA mutant gastrointestinal stromal tumors. Clin Sarcoma Res., 4, 9.","journal-title":"Clin Sarcoma Res."},{"key":"10381_CR425","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell, J. R., Muntoni, F., McDonald, C. M., et al. (2025). AAV gene therapy for Duchenne muscular dystrophy: The EMBARK phase 3 randomized trial. Nature Medicine, 31, 332\u2013341.","journal-title":"Nature Medicine"},{"key":"10381_CR426","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41434-025-00561-6","volume":"32","author":"K Chwalenia","year":"2025","unstructured":"Chwalenia, K., Feng, V. Y., Hemmer, N., et al. (2025). AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: Progress and prospects. Gene Therapy, 32, 447\u2013461.","journal-title":"Gene Therapy"},{"key":"10381_CR427","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24020953","author":"U Karmacharya","year":"2023","unstructured":"Karmacharya, U., & Jung, J. W. (2023). Small molecule inhibitors for Unc-51-like autophagy-activating kinase targeting autophagy in cancer. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms24020953","journal-title":"International Journal of Molecular Sciences"},{"key":"10381_CR428","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212402","author":"JJ Lee","year":"2021","unstructured":"Lee, J. J., Jain, V., & Amaravadi, R. K. (2021). Clinical translation of combined MAPK and autophagy inhibition in RAS mutant cancer. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms222212402","journal-title":"International Journal of Molecular Sciences"},{"key":"10381_CR429","doi-asserted-by":"publisher","first-page":"viii583","DOI":"10.1093\/annonc\/mdy299.019","volume":"29","author":"H Cho","year":"2018","unstructured":"Cho, H., Ryu, M. H., Kim, B. J., et al. (2018). Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib. Annals of Oncology, 29, viii583.","journal-title":"Annals of Oncology"},{"key":"10381_CR430","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/annonc\/mdy055","volume":"29","author":"YK Kang","year":"2018","unstructured":"Kang, Y. K., Ryu, M. H., Park, S. H., et al. (2018). Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Annals of Oncology, 29, 1220\u20131226.","journal-title":"Annals of Oncology"},{"key":"10381_CR431","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2025.43.16_suppl.1007","volume":"43","author":"S-B Kim","year":"2025","unstructured":"Kim, S.-B., Xu, B., Sun, T., et al. (2025). Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364). Journal of Clinical Oncology., 43, 1007\u20131007.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR432","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","volume":"70","author":"YJ Mi","year":"2010","unstructured":"Mi, Y. J., Liang, Y. J., Huang, H. B., et al. (2010). Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Research, 70, 7981\u20137991.","journal-title":"Cancer Research"},{"key":"10381_CR433","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1200\/JCO.2025.43.16_suppl.11524","volume":"43","author":"MC Heinrich","year":"2025","unstructured":"Heinrich, M. C., Town, A., Roberti, M., M\u00fchlenberg, T., & Bauer, S. (2025). In vitro profiling of IDRX-42 against secondary and tertiary mutations (AP\/AL) found in TKI-resistant GIST. Journal of Clinical Oncology., 43, 11524\u201311524.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR434","doi-asserted-by":"publisher","first-page":"e2053","DOI":"10.1002\/onco.13917","volume":"26","author":"JR Zalcberg","year":"2021","unstructured":"Zalcberg, J. R., Heinrich, M. C., George, S., et al. (2021). Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: An analysis of the INVICTUS study. The Oncologist, 26, e2053\u2013e2060.","journal-title":"The Oncologist"},{"key":"10381_CR435","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/ijc.32282","volume":"145","author":"S Jilg","year":"2019","unstructured":"Jilg, S., Rassner, M., Maier, J., et al. (2019). Circulating cKIT and PDGFRA DNA indicates disease activity in gastrointestinal stromal tumor (GIST). International Journal of Cancer, 145, 2292\u20132303.","journal-title":"International Journal of Cancer"},{"key":"10381_CR436","doi-asserted-by":"publisher","first-page":"e20519","DOI":"10.1200\/jco.2010.28.15_suppl.e20519","volume":"28","author":"E Fumagalli","year":"2010","unstructured":"Fumagalli, E., Coco, P., Morosi, C., Bertulli, R., & Casali, P. G. (2010). Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy. Journal of Clinical Oncology, 28, e20519\u2013e20519.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR437","doi-asserted-by":"publisher","first-page":"11038","DOI":"10.1200\/JCO.2017.35.15_suppl.11038","volume":"35","author":"B Vincenzi","year":"2017","unstructured":"Vincenzi, B., Nannini, M., Grignani, G., et al. (2017). Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey. Journal of Clinical Oncology., 35, 11038\u201311038.","journal-title":"Journal of Clinical Oncology."},{"key":"10381_CR438","doi-asserted-by":"publisher","first-page":"175883592311923","DOI":"10.1177\/17588359231192388","volume":"15","author":"C Serrano","year":"2023","unstructured":"Serrano, C., Mart\u00edn-Broto, J., Asencio-Pascual, J. M., et al. (2023). 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol., 15, 17588359231192388.","journal-title":"Ther Adv Med Oncol."},{"key":"10381_CR439","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-024-02672-0","volume":"132","author":"I Judson","year":"2025","unstructured":"Judson, I., Jones, R. L., Wong, N., et al. (2025). Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. British Journal of Cancer, 132, 1\u201310.","journal-title":"British Journal of Cancer"},{"key":"10381_CR440","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473224","volume":"45","author":"H Joensuu","year":"2025","unstructured":"Joensuu, H., Miyashita, H., George, S., & Sicklick, J. (2025). Navigating ongoing challenges in GI stromal tumors. American Society of Clinical Oncology Educational Book, 45, Article e473224.","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10381_CR441","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1186\/s12885-022-10379-9","volume":"22","author":"P Sch\u00f6ffski","year":"2022","unstructured":"Sch\u00f6ffski, P., George, S., Heinrich, M. C., et al. (2022). Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: Analysis from the phase 3 INVICTUS trial. BMC Cancer, 22, 1302.","journal-title":"BMC Cancer"},{"key":"10381_CR442","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113245","volume":"192","author":"H Gelderblom","year":"2023","unstructured":"Gelderblom, H., Jones, R. L., Blay, J. Y., et al. (2023). Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study. European Journal of Cancer, 192, Article 113245.","journal-title":"European Journal of Cancer"},{"key":"10381_CR443","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13569-019-0116-3","volume":"9","author":"L Fauske","year":"2019","unstructured":"Fauske, L., Hompland, I., Lorem, G., Bondevik, H., & Bruland, \u00d8. S. (2019). Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: A qualitative study. Clin Sarcoma Res., 9, 6.","journal-title":"Clin Sarcoma Res."},{"key":"10381_CR444","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/fon-2022-0730","volume":"19","author":"D van de Wal","year":"2023","unstructured":"van de Wal, D., Venkatesan, S., Benson, C., et al. (2023). A patient\u2019s perspective on the side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors. Future Oncology, 19, 299\u2013314.","journal-title":"Future Oncology"},{"key":"10381_CR445","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00520-023-07810-7","volume":"31","author":"D van de Wal","year":"2023","unstructured":"van de Wal, D., Fauske, L., Bruland, \u00d8. S., et al. (2023). Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: A qualitative study with patients and medical oncologists. Supportive Care in Cancer, 31, 352.","journal-title":"Supportive Care in Cancer"},{"key":"10381_CR446","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s12094-023-03177-7","volume":"25","author":"C Serrano","year":"2023","unstructured":"Serrano, C., \u00c1lvarez, R., Carrasco, J. A., et al. (2023). SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical and Translational Oncology, 25, 2707\u20132717.","journal-title":"Clinical and Translational Oncology"},{"key":"10381_CR447","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00832-5","volume":"22","author":"D G\u00f3mez-Peregrina","year":"2021","unstructured":"G\u00f3mez-Peregrina, D., Garc\u00eda-Valverde, A., Pilco-Janeta, D., & Serrano, C. (2021). Liquid biopsy in gastrointestinal stromal tumors: Ready for prime time? Current Treatment Options in Oncology, 22, Article 32.","journal-title":"Current Treatment Options in Oncology"},{"key":"10381_CR448","doi-asserted-by":"publisher","first-page":"397784","DOI":"10.1200\/JCO.2023.41.36_suppl.397784","volume":"41","author":"S Bauer","year":"2023","unstructured":"Bauer, S., Jones, R. L., George, S., et al. (2023). Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: CtDNA analysis from INTRIGUE. Journal of Clinical Oncology, 41, 397784.","journal-title":"Journal of Clinical Oncology"},{"key":"10381_CR449","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/1078-0432.CCR-25-0145","volume":"31","author":"CM Kelly","year":"2025","unstructured":"Kelly, C. M., Bradic, M., Saunds, S., et al. (2025). ctDNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumor. Clinical Cancer Research, 31, 4110\u20134121.","journal-title":"Clinical Cancer Research"},{"key":"10381_CR450","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41698-023-00421-9","volume":"7","author":"Y Fu","year":"2023","unstructured":"Fu, Y., Karanian, M., Perret, R., et al. (2023). Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor. NPJ Precis Oncol., 7, 71.","journal-title":"NPJ Precis Oncol."},{"key":"10381_CR451","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/path.6399","volume":"265","author":"X Kong","year":"2025","unstructured":"Kong, X., Shi, J., Sun, D., et al. (2025). A deep-learning model for predicting tyrosine kinase inhibitor response from histology in gastrointestinal stromal tumor. The Journal of Pathology, 265, 462\u2013471.","journal-title":"The Journal of Pathology"},{"key":"10381_CR452","doi-asserted-by":"crossref","unstructured":"Bonetti, A., Le, V.L., Carrero, Z.I., et al. (2026). Deep learning predicts mutations and outcomes in gastrointestinal stromal tumors from whole-slide images. Cancer Res.\u00a0","DOI":"10.1158\/0008-5472.CAN-26-0132"},{"key":"10381_CR453","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102200","volume":"64","author":"D Bertsimas","year":"2023","unstructured":"Bertsimas, D., Margonis, G. A., Tang, S., et al. (2023). An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: An observational cohort study. EClinicalMedicine, 64, Article 102200.","journal-title":"EClinicalMedicine"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10381-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:02:29Z","timestamp":1789801349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10381-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":453,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10381"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10381-8","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"70"}}